var title_f24_21_24912="Diabetic foot ulcer 1 PI";
var content_f24_21_24912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wagner grade 1 ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foot from a diabetic patient showing a superficial ulcer (Wagner grade 1) that involves the full thickness of the skin but no underlying tissues. This lesion healed quickly with rest and local foot care.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24912=[""].join("\n");
var outline_f24_21_24912=null;
var title_f24_21_24913="Adenomatoid malform CXR II";
var content_f24_21_24913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation (Type I) in a newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After insertion of a left chest tube, liquid is drained out of a large left lung cyst, which doesn't collapse but fills with air.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24913=[""].join("\n");
var outline_f24_21_24913=null;
var title_f24_21_24914="Calculator: Mantle Cell Lymphoma International Prognostic Index (MIPI)";
var content_f24_21_24914=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MIPI_form\" name=\"MIPI_form\" onkeydown=\"clrResults();\" onkeyup=\"MIPI_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Mantle Cell Lymphoma International Prognostic Index (MIPI)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MIPI = (0.03535 * Age) + ECOGPerformanceStatus + (1.367 * log(LDH / ULNLDH)) + (0.9393 * log(WBC))",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"MIPI_fx(); minMaxCheck();\" onchange=\"MIPI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               years old",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              ECOG Performance Status",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"ECOG_Performance_Status_radio\" onclick=\"MIPI_fx();\" type=\"radio\" value=\"PS 0: Fully active, able to carry on all pre-disease performance without restriction|0\"/>",
"              PS 0: Fully active, able to carry on all pre-disease performance without restriction (0)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"ECOG_Performance_Status_radio\" onclick=\"MIPI_fx();\" type=\"radio\" value=\" PS 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work|0\"/>",
"              PS 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work (0)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"ECOG_Performance_Status_radio\" onclick=\"MIPI_fx();\" type=\"radio\" value=\" PS 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours|0.6978\"/>",
"              PS 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours (0.6978)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"ECOG_Performance_Status_radio\" onclick=\"MIPI_fx();\" type=\"radio\" value=\" PS 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours|0.6978\"/>",
"              PS 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours (0.6978)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"ECOG_Performance_Status_radio\" onclick=\"MIPI_fx();\" type=\"radio\" value=\" PS 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair|0.6978\"/>",
"              PS 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair (0.6978)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              LDH",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"LDH_param\" onblur=\"MIPI_fx(); minMaxCheck();\" onchange=\"MIPI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"LDH_unit\" onchange=\"MIPI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|U/L_LDH\">",
"               U/L",
"              </option>",
"              <option value=\"59.9880023995201|0|mcKat/L_LDH\">",
"               mcKat/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              ULN LDH",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"ULN_LDH_param\" onblur=\"MIPI_fx(); minMaxCheck();\" onchange=\"MIPI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"ULN_LDH_unit\" onchange=\"MIPI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|U/L_LDH\">",
"               U/L",
"              </option>",
"              <option value=\"59.9880023995201|0|mcKat/L_LDH\">",
"               mcKat/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              WBC",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"WBC_param\" onblur=\"MIPI_fx(); minMaxCheck();\" onchange=\"MIPI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               #/microL",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              MIPI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"MIPI_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                points",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"MIPI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         MIPI score prognostic interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          MIPI &lt;= 5.7:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Low risk",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          MIPI &gt; 5.7 and &lt;= 6.2:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Intermediate risk",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          MIPI &gt; 6.2:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          High risk",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        LDH",
"       </b>",
"       is the patient's baseline serum lactate dehydrogenase level.",
"      </li>",
"      <li>",
"       <b>",
"        ULN LDH",
"       </b>",
"       is the upper limit of the reference range for serum",
"       <b>",
"        LDH",
"       </b>",
"       in the laboratory where the patient's",
"       <b>",
"        LDH",
"       </b>",
"       was measured.",
"      </li>",
"      <li>",
"       <b>",
"        WBC",
"       </b>",
"       is total white blood cell count.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      ECOG Performance Status",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g.  (0), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Hoster E, Dreyling M, Klapper W, et. al. A new prognostic index (MIPI) for patients with advanced-stage mantle  cell lymphoma.",
"        <i>",
"         Blood",
"        </i>",
"        . 2008 Jan 15;111(2):558-65. Epub 2007 Oct 25. Erratum in: Blood. 2008 Jun 15;111(12):5761.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24914=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function MIPI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.MIPI_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"Age = param_value;",
"if (ECOG_Performance_Status_radio[0].checked){ ECOG_Performance_Status = 0; }",
"if (ECOG_Performance_Status_radio[1].checked){ ECOG_Performance_Status = 0; }",
"if (ECOG_Performance_Status_radio[2].checked){ ECOG_Performance_Status = 0.6978; }",
"if (ECOG_Performance_Status_radio[3].checked){ ECOG_Performance_Status = 0.6978; }",
"if (ECOG_Performance_Status_radio[4].checked){ ECOG_Performance_Status = 0.6978; }",
"if (LDH_param.value.indexOf(',') >= 0){ LDH_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(LDH_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = LDH_unit.options[LDH_unit.selectedIndex].value.split('|');",
"LDH = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (ULN_LDH_param.value.indexOf(',') >= 0){ ULN_LDH_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(ULN_LDH_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = ULN_LDH_unit.options[ULN_LDH_unit.selectedIndex].value.split('|');",
"ULN_LDH = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (WBC_param.value.indexOf(',') >= 0){ WBC_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(WBC_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"WBC = param_value;",
"dp = decpts.options[decpts.selectedIndex].text;",
"MIPI =  (0.03535 * Age) + ECOG_Performance_Status + (1.367 * log(LDH / ULN_LDH)) + (0.9393 * log(WBC));",
"",
"if (doCalc) MIPI_param.value = fixDP(MIPI, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (MIPI <= 5.7){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((MIPI > 5.7) && (MIPI <= 6.2)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (MIPI > 6.2){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MIPI_form){",
"",
"if (Age_param.value && Age < 18) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 18 years old.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 years old.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (LDH_param.value && LDH < 0) {",
"LDH = 0;",
"LDH_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for LDH is 0 U/L_LDH.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (ULN_LDH_param.value && ULN_LDH < 0) {",
"ULN_LDH = 0;",
"ULN_LDH_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for ULN LDH is 0 U/L_LDH.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MIPI_form){",
"",
"MIPI_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f24_21_24914=null;
var title_f24_21_24915="Laryngomalacia video";
var content_f24_21_24915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77720/laryngom_conv.mp4?title=Laryngomalacia+video\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laryngomalacia video",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexible laryngoscopy of laryngomalacia. Note the omega-shaped epiglottis and the collapse of the supraglottic structures during inspiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24915=[""].join("\n");
var outline_f24_21_24915=null;
var title_f24_21_24916="Gabapentin enacarbil: Patient drug information";
var content_f24_21_24916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gabapentin enacarbil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/12/1222?source=see_link\">",
"     see \"Gabapentin enacarbil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12924419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Horizant&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12805094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12805096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat painful nerve diseases.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12805095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702177",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gabapentin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3860544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Restless leg syndrome:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a job that calls for you to stay awake at night.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12805100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not the same as gabapentin (Gralise&trade;, Neurotin&reg;). Do not use in its place. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12805101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12805103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12805098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3860544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Restless leg syndrome:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3434363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at 5 PM each day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12805099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12805104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12805105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16487 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24916=[""].join("\n");
var outline_f24_21_24916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12924419\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805094\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805096\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805095\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805100\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805101\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805103\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805098\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805099\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805104\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12805105\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/12/1222?source=related_link\">",
"      Gabapentin enacarbil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_21_24917="Sesamoid under 5th mcp AP";
var content_f24_21_24917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53384%7EEM%2F74938%7EEM%2F66231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53384%7EEM%2F74938%7EEM%2F66231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small sesamoid underlying the fifth metatarsophalangeal joint (white arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This AP view also shows a midshaft, nondisplaced fracture of the proximal phalanx of the little toe (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small sesamoid underlying the fifth metatarsophalangeal joint (white arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oblique view also shows the medial and lateral sesamoids below the metatarsophalangeal joint of the great toe (black arrow), and a nondisplaced, transverse fracture of the proximal phalanx of the little toe (grey arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24917=[""].join("\n");
var outline_f24_21_24917=null;
var title_f24_21_24918="Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors";
var content_f24_21_24918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24918/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24918/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24918/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24918/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24918/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24918/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/21/24918/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, commonly employed in patients with coronary heart disease, can be associated with thrombocytopenia, often within minutes to hours of the initial administration. Thrombocytopenia induced by GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors will be reviewed here. An overall approach to drug-induced thrombocytopenia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a clear association between the use of glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    ) and thrombocytopenia. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is often given with these agents, case reports and clinical trial data document that GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors are most commonly the etiology of thrombocytopenia when both agents are used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The thrombocytopenia caused by GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors is clinically distinct from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT). Thrombocytopenia caused by GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors is sudden and severe while thrombocytopenia in HIT often occurs gradually and platelet counts are rarely less than",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/2\">",
"     2",
"    </a>",
"    ]. Although paradoxical thrombosis has been reported with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/3\">",
"     3",
"    </a>",
"    ], it is very rare compared with the common occurrence of thrombosis in patients with HIT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H8#H8\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Onset and degree of thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to acute thrombocytopenia, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors can also cause pseudo- thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/4\">",
"     4",
"    </a>",
"    ]. The latter phenomenon refers to a laboratory artifact due to platelet clumping induced by the EDTA anticoagulant present in the tube in which blood samples for complete blood counts are drawn. Pseudothrombocytopenia is an in vitro artifact that is not associated with any clinical problems. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Pseudothrombocytopenia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRUE THROMBOCYTOPENIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia, at times profound, has been observed within 24 hours, and occasionally within several hours, of the initial GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. A pooled analysis of eight placebo-controlled randomized trials of the GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    increased the incidence of mild (4.2 versus 2 percent for placebo) and severe thrombocytopenia (1 versus 0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/7\">",
"     7",
"    </a>",
"    ]. Any thrombocytopenia and severe thrombocytopenia were more frequent with a bolus plus infusion of abciximab (5.6 and 1.6 percent, respectively). Other studies have documented similar significantly increased rates of thrombocytopenia for patients treated in randomized controlled studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombocytopenia associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    may result in severe bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/7\">",
"     7",
"    </a>",
"    ]. In an analysis from the TARGET trial, which was published after the meta-analysis, thrombocytopenia was seen more frequently with abciximab than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    (2.4 versus 0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with thrombocytopenia had more frequent severe bleeding (5.1 versus 0.7 percent), received blood transfusions more frequently (6.1 versus 1.4 percent), and had a higher incidence of death, myocardial infarction, or the need for target vessel revascularization at 30 days (12.2 versus 6.6 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Time course and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unique feature of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor-induced thrombocytopenia is that the thrombocytopenia typically occurs within 24 hours, and occasionally within 30 minutes to several hours of initial administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This is distinct from other drugs that cause thrombocytopenia mediated by drug-dependent anti-platelet antibodies. Development of antibodies with all other drugs requires a longer period of drug administration in order to induce sensitization and antibody formation (eg, median duration of exposure for all other drugs that cause thrombocytopenia is 14 to 21 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hypothesis to explain the rapid occurrence of thrombocytopenia following initial exposure to GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors is that patients have preformed \"naturally occurring\" antibodies against platelet neoepitopes that are exposed by alteration of the conformation of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    molecule during normal platelet aggregation (mediated by binding to fibrinogen) and perhaps during the process of senescence. These antibodies are described as reacting with ligand-induced binding sites (\"LIBS\" effect) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. These antibodies might recognize similar conformational changes in GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    induced by these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies causing acute thrombocytopenia in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    recognize murine peptide sequences incorporated into the abciximab Fab fragment that confer specificity for GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/20\">",
"     20",
"    </a>",
"    ]. The frequency of naturally occurring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    -dependent antibodies may be less than naturally occurring antibodies that cause abciximab-induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/16\">",
"     16",
"    </a>",
"    ]. Whether GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor-antibodies induce platelet clearance by simple opsonization, by inducing mild platelet activation, or both is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with the hypothesis of preformed antibodies is the demonstration of IgG antibodies reactive with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    -coated platelets in 15 of 16 patients who developed thrombocytopenia within a few hours of abciximab treatment, as well as in 15 of 150 normal subjects who had never been exposed to abciximab [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential explanation for these observations was provided by a study of patients developing severe thrombocytopenia after re-exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/20\">",
"     20",
"    </a>",
"    ]. Patient antibodies appeared to react preferentially to platelets sensitized with the intact monoclonal antibody 7E3 from which the murine sequences in abciximab were derived. In contrast, antibodies found in unexposed subjects reacted equally well to platelets sensitized to 7E3, an antibody specific for GP IIIa, or one specific for the GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    complex. These observations suggest that antibodies in patients with recurrent thrombocytopenia caused by abciximab are more specific for abciximab-induced changes than those induced during the course of normal platelet reactions and senescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Management approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the possibility of sudden and severe drug-induced thrombocytopenia, the platelet count should be monitored frequently in patients receiving GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors. A reasonable plan for patients about to be treated with these agents is to obtain a platelet count prior to treatment, within two to four hours following the intravenous bolus, daily during therapy, and again prior to the patient's discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/5\">",
"     5",
"    </a>",
"    ]. If the platelet count falls to",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    or to less than 25 percent of its pretreatment level, additional platelet counts should be obtained and the following performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of pseudothrombocytopenia should be ruled out by examination of a blood smear to rule out the presence of platelet clumping and repeating the platelet count in sodium citrate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      if platelet clumping is observed (",
"      <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pseudothrombocytopenia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If pseudothrombocytopenia is ruled out by the above procedures, the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor should be discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other potential causes of thrombocytopenia should also be excluded, including evaluation of the patient for thrombocytopenia secondary to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , often used in combination with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor. However, heparin rarely causes severe thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H15#H15\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Diagnostic testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H9#H9\">",
"       \"Drug-induced thrombocytopenia\", section on 'Initial approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Platelet transfusion should be considered if the platelet count is",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL,",
"      </span>",
"      if there is severe bleeding, or if an emergency invasive procedure is required.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      should be discontinued and its effects reversed with protamine if bleeding is present.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and other antiplatelet agents should also be stopped in the presence of severe bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia. The use of intravenous gamma globulin (IVIG) is expensive and has not been of clinical benefit in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be important differences concerning whether or not to stop",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and other antiplatelet agents when using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    , as platelet count recovery may be faster after these agents are stopped (one to &gt;5 days) than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (three days to two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/5,16,24\">",
"     5,16,24",
"    </a>",
"    ]. Direct megakaryocyte impairment by these antibodies may explain the prolonged platelet count recovery seen in some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Readministration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Readministration of these agents is not recommended after an episode of thrombocytopenia, since there may be a risk for more severe thrombocytopenia after rechallenge. This was illustrated in a prospective review of 550 patients who received a second or third dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    at least seven days after a first treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/26\">",
"     26",
"    </a>",
"    ]. Thrombocytopenia developed in 4.6 percent, was severe",
"    <span class=\"nowrap\">",
"     (&lt;20,000/microL)",
"    </span>",
"    in 2.4 percent (occurring after discharge in 0.4 percent), and recurred despite platelet transfusion in 0.8 percent.",
"   </p>",
"   <p>",
"    In a second report, the incidence of severe thrombocytopenia was 4 percent in patients re-exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , but was 12 percent if the interval between exposures was &le;2 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PSEUDOTHROMBOCYTOPENIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incidence and clinical relevance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    has also been associated with pseudothrombocytopenia. A review of four large abciximab trials found that the incidence of pseudothrombocytopenia was 2 percent, which accounted for 36 percent of low platelet counts during abciximab therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/28\">",
"     28",
"    </a>",
"    ]. Pseudothrombocytopenia was not associated with any adverse outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Pseudothrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Definition and diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the above report, pseudothrombocytopenia was defined as the presence of one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24918/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet clumping on a peripheral smear made from blood in which the offending anticoagulant was used (",
"      <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A difference between the platelet count in blood samples obtained using different anticoagulants (eg, EDTA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , citrate), with one having a count at least 20 percent lower than that of the comparison anticoagulant. The offending anticoagulant was EDTA in most of the 117 cases, although 14 were documented to occur in the presence of citrate as an anticoagulant.",
"     </li>",
"     <li>",
"      A normal platelet count on a non-anticoagulated blood sample (eg, finger stick) taken directly into platelet count diluent fluid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The \"gold standard\" for evaluation of thrombocytopenia of any cause is examination of the peripheral smear. In vitro platelet clumping, which can occur with one or more anticoagulants, especially EDTA, the routine anticoagulant employed for blood counts, can be observed and distinguished from true thrombocytopenia (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of a low platelet count is a common complication of the use of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, and may take one of the following two forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      True thrombocytopenia &mdash; True thrombocytopenia typically occurs within 24 hours, and occasionally within 30 minutes to several hours, of the initial administration of a glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'True thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudothrombocytopenia &mdash; Pseudothrombocytopenia is an artifactual finding suspected initially by finding platelet clumping on a blood smear prepared using anticoagulated blood (usually EDTA) (",
"      <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"       picture 1",
"      </a>",
"      ). It is of no clinical relevance. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pseudothrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients about to be treated with one of these agents should have a platelet count obtained prior to treatment, within two to four hours following the intravenous bolus, daily during therapy, and again prior to discharge. If the platelet count falls to",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    or to less than 25 percent of its pretreatment level, the following should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rule out the presence of pseudothrombocytopenia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Definition and diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rule out other potential causes of true thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"       \"Approach to the adult patient with thrombocytopenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H9#H9\">",
"       \"Drug-induced thrombocytopenia\", section on 'Initial approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Actions to be taken",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have severe thrombocytopenia",
"      <span class=\"nowrap\">",
"       (&le;50,000/microL)",
"      </span>",
"      without an alternative explanation should discontinue their GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor immediately.",
"     </li>",
"     <li>",
"      For patients who are actively bleeding or have additional risk factors for severe bleeding (eg, platelet count",
"      <span class=\"nowrap\">",
"       &lt;10,000/microL,",
"      </span>",
"      coagulopathy, planned invasive procedure), we also recommend platelet transfusion (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Group data available on the author's website, search on Drug-induced thrombocytopenia. www.ouhsc.edu/platelets (Accessed on February 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/2\">",
"      Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program 2006; :408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/3\">",
"      Gao C, Boylan B, Bougie D, et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest 2009; 119:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/4\">",
"      Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006; 97:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/5\">",
"      Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997; 95:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/6\">",
"      Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/7\">",
"      Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000; 140:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/8\">",
"      Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004; 109:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/9\">",
"      Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/10\">",
"      Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/11\">",
"      A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/12\">",
"      George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/13\">",
"      Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997; 52:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/14\">",
"      Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/15\">",
"      Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/16\">",
"      Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/17\">",
"      Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99:3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/18\">",
"      Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 2008; 111:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/19\">",
"      Bougie DW, Rasmussen M, Zhu J, Aster RH. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of &alpha;IIb/&beta;3 integrin. Blood 2012; 119:6317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/20\">",
"      Curtis BR, Swyers J, Divgi A, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/21\">",
"      Curtis BR, McFarland JG, Garrity MM, et al. Thrombocytopenia induced by abciximab: Studies of pathogenesis (abstract). Blood 1998; 92:181a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/22\">",
"      Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2000; 9:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/23\">",
"      Kereiakes DJ, Essell JH, Abbottsmith CW, et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/24\">",
"      Paradiso-Hardy FL, Madan M, Radhakrishnan S, et al. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter Cardiovasc Interv 2001; 54:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/25\">",
"      Greinacher A, Fuerll B, Zinke H, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009; 114:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/26\">",
"      Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/27\">",
"      Madan M, Kereiakes DJ, Hermiller JB, et al. Efficacy of abciximab readministration in coronary intervention. Am J Cardiol 2000; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24918/abstract/28\">",
"      Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6685 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24918=[""].join("\n");
var outline_f24_21_24918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRUE THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Time course and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Management approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Readministration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PSEUDOTHROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incidence and clinical relevance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Definition and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Actions to be taken",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6685|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 1\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_21_24919="Diagnosis of peptic ulcer disease";
var content_f24_21_24919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Nimish B Vakil, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24919/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/21/24919/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major considerations in diagnosis of peptic ulcer disease (PUD): determining whether dyspeptic symptoms are due to PUD and determining the specific etiology of an ulcer discovered by endoscopy or radiography. Symptoms alone cannot reliably distinguish PUD from other causes of dyspepsia.",
"   </p>",
"   <p>",
"    The diagnosis is generally established by upper endoscopy, although the need to pursue a definitive diagnosis depends upon the clinical setting. As an example, establishing a definitive diagnosis is always required in patients over the age of 55 years and in patients with gastrointestinal bleeding or other alarm symptoms (such as early satiety, dysphagia, weight loss, occult gastrointestinal bleeding, or otherwise unexplained anemia), although these alarm features have limited value in predicting an underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/1\">",
"     1",
"    </a>",
"    ]. By contrast, empiric testing for H. pylori may be appropriate in young patients without alarm symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=see_link\">",
"     \"Clinical manifestations of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss diagnostic studies in patients who may have a peptic ulcer, and provide an overall approach to the diagnosis. The treatment of PUD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BLOOD TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established blood tests that can reliably predict the presence of PUD. However, a complete blood count and blood chemistries (including liver function tests and serum calcium levels) are generally obtained. Normal values on these tests are reassuring while abnormalities may help to guide further testing. Unexpected anemia, for example, warrants a detailed evaluation and may raise concern for an underlying malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENDOSCOPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Detection of ulcer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is the most accurate diagnostic test for peptic ulcer disease (PUD). Sensitivity of endoscopy depends in part upon the location of the ulcer, the experience of the endoscopist, and the \"gold\" standard used. Experienced endoscopists detect about 90 percent of gastroduodenal lesions found by a second endoscopist, by radiography, or at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differentiation of benign gastric ulcers from cancer at endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign ulcers have smooth, regular, rounded edges, with a flat, smooth ulcer base often filled with exudate (",
"    <a class=\"graphic graphic_picture graphicRef63114 \" href=\"UTD.htm?11/37/11871\">",
"     picture 1",
"    </a>",
"    ). By contrast, the following features are suggestive of malignancy on endoscopy or radiography:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The ulcerated mass protrudes into the lumen",
"     </li>",
"     <li>",
"      The folds surrounding the ulcer crater are nodular, clubbed, fused, or stop short of the ulcer margin",
"     </li>",
"     <li>",
"      The margins are overhanging, irregular, or thickened",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple biopsies of gastric ulcers (GUs) are necessary, and should be performed even for lesions with a benign endoscopic appearance since benign-appearing ulcers may harbor malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/4\">",
"     4",
"    </a>",
"    ]. The chance of malignancy is greater in large GUs, but cancer can be found in lesions less than 1 cm. The optimal number of biopsies has been debated and probably depends upon the technique; four jumbo biopsies of the ulcer margin are equivalent to six to seven regular-sized biopsies, the number shown to detect the vast majority of cancers.",
"   </p>",
"   <p>",
"    In an illustrative study, which focused on patients with proven gastric cancer, the first regular-sized biopsy specimen yielded a correct diagnosis in 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/4\">",
"     4",
"    </a>",
"    ]. Four biopsy specimens increased the yield to greater than 95 percent, while seven specimens yielded the correct diagnosis in greater than 98 percent of cases. Seven biopsy and cytology specimens yielded the correct diagnosis in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Follow-up endoscopy to exclude malignant GU",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale behind endoscopic follow-up of a patient with a GU is that the absence of symptoms does not reliably exclude malignancy and surveillance endoscopy may identify patients with gastric cancer at an early stage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Whether follow-up endoscopy actually improves survival is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform surveillance endoscopy in patients with GUs should be individualized. We suggest a surveillance endoscopy be performed in patients with a GU who remain symptomatic despite medical therapy, in patients with GUs without a clear etiology, and in those who did not undergo biopsy on initial upper endoscopy. Although the evidence to support these recommendations is limited, these recommendations are consistent with the 2010 American Society for Gastrointestinal Endoscopy guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/5,7-14\">",
"     5,7-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also suggest that a repeat upper endoscopy be performed when there is concern that the initial histology was inadequate, the endoscopic appearance was not clearly benign, the initial endoscopy was performed for bleeding; or, when risks factors for malignancy are present (eg, age &gt;50 years,",
"    <em>",
"     H. pylori",
"    </em>",
"    , migration from a region with high prevalence of gastric cancer, family history of gastric cancer, ulcer size, and the presence of gastric atrophy, adenoma, dysplasia, possibly intestinal metaplasia, and low serum pepsinogen) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If follow-up endoscopy is performed, biopsies of the ulcer bed should be obtained, even if the ulcer has healed, as a malignancy or high-grade dysplasia may be detected in apparently healed ulcers. This is particularly important in patients on antisecretory agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BARIUM RADIOGRAPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Detection of ulcer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advances and availability of endoscopy over the last 30 years, upper gastrointestinal radiography has been relegated to a limited role in the diagnosis of peptic ulcer disease (PUD). However, it still continues to be performed in patients who are not eligible or unwilling to undergo endoscopy, or where endoscopy is unavailable. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Endoscopy versus barium radiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A definitive radiographic diagnosis of peptic ulcer requires demonstration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    within an ulcer niche, which is generally round or oval and may be surrounded by a smooth mound of edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Secondary changes include folds radiating to the crater, and deformities in the region secondary to spasm, edema, and scarring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary changes of GU include folds radiating to the crater and deformities in the region secondary to spasm, edema, and scarring (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76712 \" href=\"UTD.htm?30/56/31630\">",
"       image 1",
"      </a>",
"      ). The incisura can be found encircling a GU due to the secondary spasm of circular muscle.",
"     </li>",
"     <li>",
"      Secondary signs of DU include deformity of the duodenal bulb that may be evidenced by flattening of the superior or inferior fornices, eccentricity of the pyloric channel, pseudodiverticula, or exaggerated outpouching of recesses at the base of the bulb [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the presence of deformity of the duodenal bulb, edema of the folds, or postoperative deformity, ulcer craters become much more difficult to detect. Shallow lesions &lt;0.5 cm in diameter are also difficult to detect reliably. False positive results occur when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    is trapped between folds. Thus, it is important to document that the configuration of a suspected crater is constant on multiple X-ray views.",
"   </p>",
"   <p>",
"    The sensitivity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography for detecting ulcers reflects the technique, skill, and interest of the radiologist, the ability of the patient to cooperate, and the size and location of the ulcer. Because of the near universal shift to endoscopy over the past 25 years, there are few radiologists with expertise at upper gastrointestinal radiography. Thus, accuracy in practice is unlikely to achieve the results reported in earlier studies.",
"   </p>",
"   <p>",
"    Single contrast radiographic techniques miss as many as 50 percent of DUs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, in experienced hands about 80 percent of DUs can be detected with procedures using double contrast, compression, or hypotonic duodenography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The optimal technique appears to be a combined \"biphasic\" approach, including spot views during vigorous compression with the bulb filled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    to improve the detection of anterior ulcers, and double contrast to improve the detection of posterior ulcers. The detection of GUs also varies considerably as a function of technique [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiographic differentiation of benign versus malignant lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although benign GUs are more frequently found on the lesser curvature at the incisura, they can occur anywhere, as can gastric cancers. Thus, location is of little value in predicting the presence or absence of malignancy. In contrast, several other features suggest the presence of gastric cancer on radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ulcer within a definitive mass protruding into the lumen",
"     </li>",
"     <li>",
"      Effaced, interrupted, fused, or nodular mucosal folds as they approach the margin of the crater",
"     </li>",
"     <li>",
"      Negative irregular filling defects in the ulcer crater, although an irregular base also may result from the presence of blood clots, granulation tissue, or other debris.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only definitive way to rule out malignancy is direct inspection with adequate biopsy. However, the following radiographic signs of benignancy may be useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation of smooth, symmetric mucosal folds to the edge of the ulcer crater or to a smooth mound of edema (ulcers should not be considered radiologically benign without an en face view demonstrating this feature)",
"     </li>",
"     <li>",
"      A smooth translucent band or collar surrounding the ulcer crater, suggesting edema (differentiation from an infiltrating mass with central ulceration is critical)",
"     </li>",
"     <li>",
"      Hampton's sign, which is a radiolucent line about 1 mm in width that rims the mouth of the ulcer crater, resulting from undermining of normal mucosa (reliable, if present, but insensitive)",
"     </li>",
"     <li>",
"      An incisura or indentation on the opposite wall due to edema and spasm of circular muscle",
"     </li>",
"     <li>",
"      Extension of a crater outside the contour of the gastric lumen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ENDOSCOPY VERSUS BARIUM RADIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopy is the appropriate first test for evaluating gastric malignancy.",
"   </p>",
"   <p>",
"    However, enlarged folds and spasm can obscure ulcer visualization at endoscopy, but pose even a bigger problem with radiography. Radiography is also limited by requiring patient cooperation and its inability to provide direct visualization and biopsies. However, radiography can detect abnormalities in the mucosal contour that may not be evident at endoscopy. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    or anticholinergic agents to reduce spasm increases the endoscopic and the radiographic yield.",
"   </p>",
"   <p>",
"    In countries with a high prevalence of gastric cancer, digital",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography is an effective screening tool in combination with serum pepsinogen assays for detecting gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening and prevention of gastric cancer\", section on 'Screening programs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HELICOBACTER PYLORI TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori testing is indicated in several settings and the decision process must be adapted to circumstance, as considered below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     H. pylori testing with a known ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an ulcer is discovered by endoscopy or radiography, it is important to determine if H. pylori is present before treating with antibiotics. At endoscopy, a biopsy for urease testing will be highly accurate and inexpensive. However, results must be interpreted in light of the pretest prevalence for H. pylori. When an ulcer is demonstrated at endoscopy (especially in the absence of NSAID use), pretest prevalence of H. pylori is high and thus positive biopsy tests have high probability of being true positives, whereas negative tests are more frequently falsely negative. Therefore, a negative test should be followed by a second test to confirm the absence of H. pylori. Breath or stool antigen testing for H. pylori are appropriate alternatives if noninvasive testing is needed.",
"   </p>",
"   <p>",
"    The prompt diagnosis of H. pylori is particularly important for patients with acute bleeding due to a peptic ulcer so that they can be appropriately treated with antibiotics as soon as they are stabilized and eating a full diet. However, in practice, many patients with bleeding do not undergo H. pylori testing during the hospitalization and never receive appropriate treatment. Urease testing on biopsies lacks sensitivity in the presence of acute bleeding. Stool H. pylori antigen tests appear to lack specificity when blood is present in the stool, apparently due to cross reactivity with blood constituents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, urea breath tests during hospitalization appear to be accurate in the face of acute bleeding, detecting 86 percent of H. pylori positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/25\">",
"     25",
"    </a>",
"    ]. The one limitation is that sensitivity decreases with the increasing duration of antisecretory therapy. As a result, the breath test should be done as early during the hospitalization as possible. Furthermore, follow-up H. pylori testing should be done for any patient with negative testing during the acute phase of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     H. pylori testing for patients with upper GI symptoms before endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal in evaluating a patient with upper gastrointestinal symptoms is to expeditiously arrive at a definitive diagnosis, without unnecessarily exposing patients to costly and potentially risky diagnostic procedures. Decisions must be made and data interpreted in light of specific patient characteristics and presenting symptoms, such as patient age, index event, known ulcer history, prior work-up, socioeconomic background, and the country of origin. A strategy to test and treat for H. pylori is recommended in Western countries in patients who are under the age of 50 years old and is cost-effective in economic models [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/26\">",
"     26",
"    </a>",
"    ]. In clinical trials, this strategy has been shown to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/27\">",
"     27",
"    </a>",
"    ]. In Asia the age threshold for early endoscopy may be substantially lower due to the risk of malignancy at a young age and needs to be individualized to the population. Patients who have emigrated from high to low risk regions should still be treated as if they are at higher risk.",
"   </p>",
"   <p>",
"    The pre-test probability of H. pylori infection should be estimated because it will influence interpretation of test results. As an example, the likelihood that a 25-year-old with dyspepsia who grew up in a high socioeconomic environment has H. pylori is about 10 percent. Assuming that the sensitivity and specificity of urease biopsy or breath testing are 90 and 95 percent, respectively, the negative predictive value would be 99 percent, but the positive predictive value would be only 67 percent. If serology, with a specificity of 80 percent, were used as the screening test, the positive predictive value falls to only 33 percent. Under these circumstances, a second specific test to confirm positive results is recommended, unless specificity of the initial test approaches 100 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By contrast, in an 80-year-old patient with a documented ulcer who grew up in a low socioeconomic environment, the probability of H. pylori remains high. Thus, a positive urea breath test would have a high positive predictive value, whereas a negative test would have a high probability of being falsely negative. In this latter instance, a second test to confirm negative results is essential. An important caveat is that the prevalence of H. pylori is falling in at least some of the previously high risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly the likelihood of underlying malignancy needs to be estimated. The predictive value of alarm symptoms, such as dysphagia, weight loss, and early satiety, is not very high because many patients with benign disorders also report these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]. Nonetheless, most patients with an upper GI malignancy present with alarm symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/30\">",
"     30",
"    </a>",
"    ]. Therefore, current guidelines recommend early endoscopy for the evaluation of new onset dyspepsia in patients who are older than 55 years and in patients with alarm symptoms, regardless of age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24919/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link&amp;anchor=H63379815#H63379815\">",
"     \"Approach to the patient with dyspepsia\", section on 'Patient with alarm features or age &gt;55 years'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, regardless of whether evaluating dyspeptic symptoms or an ulcer, it is important to look for alarm features of serious organic disease, such as early satiety, dysphagia, weight loss, occult gastrointestinal bleeding, or otherwise unexplained anemia (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 1",
"    </a>",
"    ). In addition, use of drugs that may cause dyspepsia or ulcers, especially NSAIDs, should be sought. Because surreptitious NSAID use is high, especially in complicated or refractory ulcers, extra effort should be made to exclude NSAID use, including taking a medication history from family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH WITH ESTABLISHED ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain diagnostic considerations apply to patients with identified ulcer disease. If the patient has a DU, it is initially necessary only to establish H. pylori status, as indicated above. Biopsy of the DU is only indicated for refractory ulcers or lesions that are suggestive of malignancy. By contrast, all GUs warrant thorough biopsy at the first endoscopy. The necessity of follow-up endoscopy and biopsy for GU to ensure healing and to exclude malignancy is a clinical decision that rests on the adequacy of the initial biopsies and the patient's risk for gastric malignancy, as considered above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Unusual causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. pylori and NSAIDs are responsible for most peptic ulcer disease (PUD). However, a variety of other causes of PUD has been described and should be considered in the appropriate clinical setting, especially when H. pylori and use of NSAIDs have been confidently excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms alone cannot reliably distinguish peptic ulcer disease (PUD) from other causes of dyspepsia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decisions regarding the diagnostic approach must be made and data interpreted in light of specific patient characteristics and presenting symptoms, such as patient age, index event, known ulcer history, prior work-up, socioeconomic background, and country of origin.",
"     </li>",
"     <li>",
"      All patients should be assessed for alarm markers of serious organic disease, such as early satiety, dysphagia, weight loss, occult gastrointestinal bleeding, or otherwise unexplained anemia (",
"      <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"       table 1",
"      </a>",
"      ). In addition, use of drugs that may cause dyspepsia or ulcers, especially nonsteroidal antiinflammatory drugs (NSAIDs), should be sought.",
"     </li>",
"     <li>",
"      In patients in whom confirmation of the diagnosis is desired, we recommend endoscopy (rather than a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      study). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to identify the specific etiology of a newly diagnosed peptic ulcer. We recommend that patients with established PUD be tested for H. pylori and the results interpreted based upon the pretest probability of H. pylori infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'H. pylori testing for patients with upper GI symptoms before endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with gastric ulcers, characteristics of the ulcer at endoscopy should be noted and biopsies obtained to exclude malignancy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differentiation of benign gastric ulcers from cancer at endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although H. pylori and NSAIDs are most commonly implicated in PUD, a variety of other causes have been described and should be considered in the appropriate clinical setting, especially when H. pylori and use of NSAIDs have been confidently excluded. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"       \"Unusual causes of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with acute GI bleeding or perforation undergo H. pylori testing as early in the hospitalization as possible so that definitive therapy can be initiated when the patient is ready to start oral antibiotics. A biopsy for urease testing obtained during endoscopy is appropriate but not always feasible and, when negative, does not confidently exclude the presence of H. pylori. If a biopsy was not performed or if the results were negative, then a urea breath test is an accurate and convenient alternative that should be performed as early in the hospitalization as possible. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Helicobacter pylori testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to perform a follow-up endoscopy for a benign-appearing GU is controversial. We suggest that a repeat endoscopy be performed when there is concern that the initial histology was inadequate, the endoscopic appearance was questionable, the initial endoscopy was performed for bleeding; or, when risks factors for malignancy are present (eg, gastric atrophy, dysplasia, H. pylori, low serum pepsinogen values, absence of NSAID use, larger GU, age over 50, positive family history, or migration from a region of high gastric cancer prevalence). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Follow-up endoscopy to exclude malignant GU'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/1\">",
"      Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006; 295:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/2\">",
"      Cotton PB, Shorvon PJ. Analysis of endoscopy and radiography in the diagnosis, follow-up and treatment of peptic ulcer disease. Clin Gastroenterol 1984; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/3\">",
"      Dooley CP, Larson AW, Stace NH, et al. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med 1984; 101:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/4\">",
"      Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/5\">",
"      Eckardt VF, Giessler W, Kanzler G, Bernhard G. Does endoscopic follow-up improve the outcome of patients with benign gastric ulcers and gastric cancer? Cancer 1992; 69:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/6\">",
"      Stephens MR, Lewis WG, White S, et al. Prognostic significance of alarm symptoms in patients with gastric cancer. Br J Surg 2005; 92:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/7\">",
"      Bytzer P. Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile? Scand J Gastroenterol 1991; 26:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/8\">",
"      Kochman ML, Elta GH. Gastric ulcers--when is enough enough? Gastroenterology 1993; 105:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/9\">",
"      Todd JA, Richards CJ, Dixon A, Robinson RJ. Gastric ulcer and malignancy--is there a need for follow-up endoscopy? Aliment Pharmacol Ther 2004; 19:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/10\">",
"      Maniatis AG, Eisen GM, Brazer SR. Endoscopic discrimination of gastric ulcers. J Clin Gastroenterol 1997; 24:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/11\">",
"      Bustamante M, Devesa F, Borghol A, et al. Accuracy of the initial endoscopic diagnosis in the discrimination of gastric ulcers: is endoscopic follow-up study always needed? J Clin Gastroenterol 2002; 35:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/12\">",
"      Hopper AN, Stephens MR, Lewis WG, et al. Relative value of repeat gastric ulcer surveillance gastroscopy in diagnosing gastric cancer. Gastric Cancer 2006; 9:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/13\">",
"      Gurin NN, Logunov KV. [Effectiveness of differential diagnosis of benign and malignant ulcers at endoscopy]. Ter Arkh 1998; 70:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/14\">",
"      ASGE Standards of Practice Committee, Banerjee S, Cash BD, et al. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc 2010; 71:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/15\">",
"      Hosokawa O, Watanabe K, Hatorri M, et al. Detection of gastric cancer by repeat endoscopy within a short time after negative examination. Endoscopy 2001; 33:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/16\">",
"      Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/17\">",
"      Farinati F, Cardin F, Di Mario F, et al. Early and advanced gastric cancer during follow-up of apparently benign gastric ulcer: significance of the presence of epithelial dysplasia. J Surg Oncol 1987; 36:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/18\">",
"      Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000; 46:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/19\">",
"      Levine MS. Role of the double-contrast upper gastrointestinal series in the 1990s. Gastroenterol Clin North Am 1995; 24:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/20\">",
"      Glick SN. Duodenal ulcer. Radiol Clin North Am 1994; 32:1259.",
"     </a>",
"    </li>",
"    <li>",
"     Laufer I, Levine MS. Double Contrast Gastrointestinal Radiography, 2nd, Laufer I, Levine MD (Eds), WB Saunders, Philadelphia 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/22\">",
"      Ohata H, Oka M, Yanaoka K, et al. Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. Cancer Sci 2005; 96:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/23\">",
"      Lin HJ, Lo WC, Perng CL, et al. Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers. Helicobacter 2004; 9:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/24\">",
"      van Leerdam ME, van der Ende A, ten Kate FJ, et al. Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. Am J Gastroenterol 2003; 98:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/25\">",
"      Gisbert JP, Esteban C, Jimenez I, Moreno-Otero R. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter 2007; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/26\">",
"      Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/27\">",
"      Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008; 336:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/28\">",
"      McJunkin B, Sissoko M, Levien J, et al. Dramatic decline in prevalence of Helicobacter pylori and peptic ulcer disease in an endoscopy-referral population. Am J Med 2011; 124:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/29\">",
"      Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/30\">",
"      Canga C 3rd, Vakil N. Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. Am J Gastroenterol 2002; 97:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24919/abstract/31\">",
"      Talley NJ, Vakil N, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100:2324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 28 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24919=[""].join("\n");
var outline_f24_21_24919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BLOOD TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Detection of ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differentiation of benign gastric ulcers from cancer at endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Follow-up endoscopy to exclude malignant GU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BARIUM RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Detection of ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiographic differentiation of benign versus malignant lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ENDOSCOPY VERSUS BARIUM RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HELICOBACTER PYLORI TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      H. pylori testing with a known ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      H. pylori testing for patients with upper GI symptoms before endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC APPROACH WITH ESTABLISHED ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Unusual causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/28\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/28|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/56/31630\" title=\"diagnostic image 1\">",
"      Benign gastric ulcer UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/28|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/37/11871\" title=\"picture 1\">",
"      Duodenal ulcer Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/28|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/2/9259\" title=\"table 1\">",
"      Dyspepsia alarm features AGA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=related_link\">",
"      Screening and prevention of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_21_24920="Diclofenac (topical): Drug information";
var content_f24_21_24920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=see_link\">",
"    see \"Diclofenac (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=see_link\">",
"    see \"Diclofenac (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8016814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flector&reg;;",
"     </li>",
"     <li>",
"      Pennsaid&reg;;",
"     </li>",
"     <li>",
"      Solaraze&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg; Gel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pennsaid&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg; Emulgel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8017363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID);",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8017006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoarthritis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical gel (Voltaren&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Maximum total body dose of 1% gel should not exceed 32 g per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lower extremities: Apply 4 g of 1% gel to affected area 4 times/day (maximum: 16 g per joint per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Upper extremities: Apply 2 g of 1% gel to affected area 4 times/day (maximum: 8 g per joint per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical solution: Knee:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     U.S. labeling: Apply 40 drops 4 times/day to each affected knee",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Canadian labeling: Apply 40 drops 4 times/day",
"     <b>",
"      or",
"     </b>",
"     50 drops 3 times/day to each affected knee for up to 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Actinic keratosis (AK):",
"     </b>",
"     Topical (Solaraze&reg; Gel): Apply 3% gel to lesion area twice daily for 60-90 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute pain (strains, sprains, contusions):",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patch: Apply 1 patch twice daily to most painful area of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel (Voltaren&reg; Emulgel&trade; [CAN; not available in U.S.]): Apply 2-4 g to the skin over affected area(s) 3 or 4 times/day for up to 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13713274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=see_link\">",
"      see \"Diclofenac (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acute pain (strains, sprains, contusions):",
"     </b>",
"     Topical gel (Voltaren&reg; Emulgel&trade; [CAN; not available in U.S.]): Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8017029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific dosing recommendations; elderly may demonstrate adverse effects at lower doses than younger adults, and &gt;60% may develop asymptomatic peptic ulceration with or without hemorrhage; monitor renal function.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8017238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solaraze&reg;: 3% (100 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg; Gel: 1% (100 g) [contains isopropyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal, as epolamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flector&reg;: 1.3% (30s) [contains metal; 180 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pennsaid&reg;: 1.5% (150 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9550525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as diethylamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren&reg; Emulgel&trade;: 1.16% (20 g, 50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pennsaid&reg;: 1.5% (15 ml, 30 mL, 60 mL, 120 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8016851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8016847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Flector&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088598.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088598.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Pennsaid&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191085.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM191085.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Voltaren&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8017033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical gel: Do not cover with occlusive dressings or apply sunscreens, cosmetics, lotions, moisturizers, insect repellents or other topical medications to affected area. Do not wash area for one hour following application. Wash hands immediately after application (unless hands are treated joint). Avoid sunlight to exposure areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% formulation: Apply gel to affected area or joint and rub into skin gently, making sure to apply to entire affected area or joint.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% formulation: Apply to lesion with gel and smooth into skin gently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical solution: Apply to clean, dry, intact skin; do not apply to eyes, mucous membranes, or open wounds. Wash hands before and after use. Apply 10 drops at a time either directly onto knee",
"     <b>",
"      or",
"     </b>",
"     into hand then onto knee (helps avoid spillage). Repeat procedure until total dose applied. Spread evenly around knee (front, back, sides). Allow knee to dry before applying clothing. Do not shower or bathe for at least 30 minutes after applying. Do not apply heat or occlusive dressing to treated knee; protect treated knee from sunlight. Cosmetics, insect repellant, lotion, moisturizer, sunscreens, or other topical medication may be applied to treated knee once solution has dried.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Apply to intact, nondamaged skin. Remove transparent liner prior to applying to skin. Wash hands after applying as well as after removal of patch. May tape down edges of patch, if peeling occurs. Should not be worn while bathing or showering. Fold used patches so the adhesive side sticks to itself; dispose of used patches out of reach of children and pets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8016852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical gel 1%: Relief of osteoarthritis pain in joints amenable to topical therapy (eg, ankle, elbow, foot, hand, knee, wrist)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling): Relief of pain associated with acute, localized joint/muscle injuries (eg, sports injuries, strains) in patients &ge;16 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical gel 3%: Actinic keratosis (AK) in conjunction with sun avoidance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical patch: Acute pain due to minor strains, sprains, and contusions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical solution: Relief of osteoarthritis pain of the knee",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8016846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Diflucan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Voltaren&reg; may be confused with traMADol, Ultram&reg;, Verelan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch (Flector&reg;) contains conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8016915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Topical gel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Local: Application site reactions (incidence increased with 3% gel): Pruritus (&le;52%), rash (35% to 46%), contact dermatitis (4% to 33%), dry skin (&le;27%), pain (15% to 26%), exfoliation (3% gel; 6% to 24%), paresthesia (&le;20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10% (reported for 3% gel):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, skin ulcer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local:  Alopecia, edema, photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular and skeletal: Arthralgia, arthrosis, back pain, CPK increased, hypokinesia, myalgia, neck pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, pneumonia, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Topical solution:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &gt;10%: Dermatologic: Dry skin (application site 32%;  nonapplication site 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Contact dermatitis (2% to 9%), rash (3%), bruising (2%), pruritus (application site4%; nonapplication site 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (8%), abdominal pain (6%), diarrhea (4%), flatulence (4%), nausea (4%), constipation (3%), halitosis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Sinusitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Abnormal vision, allergic reaction, appetite decreased, asthma, back pain, blurred vision, body odor, cataract, chest pain, creatinine increased, depression, dizziness, drowsiness, dyspnea, ear pain, eczema, eye pain, facial edema, gastroenteritis, headache, laryngismus, laryngitis, leg cramps, lethargy, mouth ulceration, myalgia, neck rigidity, pain, palpitation, rectal hemorrhage, skin discoloration, ulcerative stomatitis, taste perversion, urticaria, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Transdermal patch:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, hypaesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dermatitis (2%), dermal allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (3%), dysgeusia (2%), abdominal pain, constipation, diarrhea, gastritis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Application site dryness, irritation, erythema, atrophy, discoloration, hyperhidrosis, and vesicles, edema, itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8016862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diclofenac or any component of the formulation; patients who exhibited asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; do not apply to nonintact or damaged skin (eg, exudative dermatitis, eczema, infected lesions, burns, or wounds)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Pennsaid&reg;: Concomitant use with other diclofenac containing products or other NSAIDS; active peptic ulcer; history of recurrent GI ulceration; active GI inflammatory disease; significant hepatic impairment or active hepatic disease; severely impaired or deteriorating renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); use in children; pregnancy; breast-feeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Voltaren&reg; Emulgel&trade;: Concomitant use with other diclofenac-containing products or other NSAIDS",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8016912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Transaminase elevations have been observed with chronic use, generally within in the first 2 months of therapy, but may occur at any time (manufacturer labeling). A recent clinical trial concluded that transaminase elevations occur 4-6 months after initiation of therapy (Laine, 2009). Significant elevations in transaminases (eg, &gt;3 x ULN) occur before patients become symptomatic. Periodic transaminase monitoring should occur in patients on chronic therapy beginning 4-8 weeks after initiation. Rarely, severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use. Use with caution in patients with hepatic porphyria (may trigger attack). Patients should be educated about symptoms of hepatotoxicity. Avoid concurrent hepatotoxins if possible and use the lowest effective dose for the shortest duration. Discontinue therapy if hepatic injury is suspected (persistent or worsening LFT abnormality, clinical signs/symptoms of liver disease, or systemic manifestations of hypersensitivity [eg, eosinophilia, rash]).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity. Do not apply topical products including transdermal diclofenac to open skin wounds, infected areas, exfoliative dermatitis, eyes or mucous membranes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical solution: Combination use with oral NSAIDs is not recommended due to increased risk of adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: Contains conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8016919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8016920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Diclofenac (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8017406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (topical gel 3%) / C (topical gel 1%, topical solution, topical patch) / D (topical solution &ge;30 weeks gestation) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8017407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the pregnancy category is product dependent (B topical gel 3%; C topical gel 1% and topical patch). When administered orally, diclofenac crosses the placenta. The amount of diclofenac available systemically following topical application is less in comparison to oral doses. Because it may cause prenatal constriction of the ductus arteriosus, the use of diclofenac topical late in pregnancy should be avoided. Reversible constriction of the ductus arteriosus",
"     <i>",
"      in utero",
"     </i>",
"     has been observed following topical application of diclofenac. Additional adverse fetal and maternal effects have been observed following oral use of diclofenac. Refer to the Diclofenac (Systemic) monograph for details. A registry is available for pregnant women exposed to autoimmune medications including diclofenac. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9771881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9771880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, low concentrations of diclofenac can be found in breast milk. Refer to the Diclofenac (Systemic) monograph for details. Because of the potential for adverse events to the nursing infant, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother (per manufacturer).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8017265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Solaraze Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (100 g): $931.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Voltaren Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (100 g): $39.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch",
"     </b>",
"     (Flector Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.3% (30): $243.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Pennsaid Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5% (150 mL): $231.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11370204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     CBC, liver enzymes (periodically during chronic therapy starting 4-8 weeks after initiation), BUN/serum creatinine; monitor urine output; occult blood loss",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Almiral Gel (MY, SG, TW);",
"     </li>",
"     <li>",
"      Arthosure (PK);",
"     </li>",
"     <li>",
"      Berafen Gel (PY);",
"     </li>",
"     <li>",
"      Berifen Gel (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Canfol (TW);",
"     </li>",
"     <li>",
"      Cataflam (VE);",
"     </li>",
"     <li>",
"      Cataflam Emulgel (BR);",
"     </li>",
"     <li>",
"      Clofec Gel (HK);",
"     </li>",
"     <li>",
"      Curinflam (AR, HK);",
"     </li>",
"     <li>",
"      Diclac (EE);",
"     </li>",
"     <li>",
"      Dicloren (TW);",
"     </li>",
"     <li>",
"      Doroxan (HK);",
"     </li>",
"     <li>",
"      Dosanac (TH);",
"     </li>",
"     <li>",
"      Fenagel (TH);",
"     </li>",
"     <li>",
"      Flexy Gel (TH);",
"     </li>",
"     <li>",
"      Flogosin D (UY);",
"     </li>",
"     <li>",
"      Galtaren (ID);",
"     </li>",
"     <li>",
"      Lofenac (TH);",
"     </li>",
"     <li>",
"      Megatic Emulgel (ID);",
"     </li>",
"     <li>",
"      Myfenax (TH);",
"     </li>",
"     <li>",
"      N-Ke'ev Gel (IL);",
"     </li>",
"     <li>",
"      N-Zen Gel (TH);",
"     </li>",
"     <li>",
"      Nac Gel (IN);",
"     </li>",
"     <li>",
"      Novo-Difenac (HK);",
"     </li>",
"     <li>",
"      Olfen (TT);",
"     </li>",
"     <li>",
"      Olfen Gel (MY, SG);",
"     </li>",
"     <li>",
"      Painelief Cool Gel (TH);",
"     </li>",
"     <li>",
"      Panaflex Extra (MY);",
"     </li>",
"     <li>",
"      Panaflex Extra Gel (SG);",
"     </li>",
"     <li>",
"      Panamax Gel (SG);",
"     </li>",
"     <li>",
"      Panamax Patch (SG);",
"     </li>",
"     <li>",
"      Physicare Gel (IL);",
"     </li>",
"     <li>",
"      Relaxyl Gel (IN);",
"     </li>",
"     <li>",
"      Remethan Gel (SG, TW);",
"     </li>",
"     <li>",
"      Renvol Emulgel (ID);",
"     </li>",
"     <li>",
"      Solaraze (DE, DK, FI, NO, PT, SE);",
"     </li>",
"     <li>",
"      Solaraze Gel (AU);",
"     </li>",
"     <li>",
"      Swiss Relief (IL);",
"     </li>",
"     <li>",
"      Uniren (SG);",
"     </li>",
"     <li>",
"      Voltadex Emulgel (ID);",
"     </li>",
"     <li>",
"      Voltareactigo (FR);",
"     </li>",
"     <li>",
"      Voltaren Emulgel (AR, AU, BE, CH, CN, CO, CZ, DE, DK, EE, FI, ID, MY, NO, PE, PH, SE, TH, TR, TW);",
"     </li>",
"     <li>",
"      Voltarene Emulgel (FR);",
"     </li>",
"     <li>",
"      Voltarol Emulgel (GB, IE);",
"     </li>",
"     <li>",
"      Voltex Kool (HK);",
"     </li>",
"     <li>",
"      Voren Gel (PH);",
"     </li>",
"     <li>",
"      Voveran Emulgel (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8016951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical gel: 6% to 10%; Topical solution: ~2% to 3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Patch: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Flector&reg;: 10-20 hours; Pennsaid&reg;: 5-17 hours; Solaraze&reg; Gel: ~5 hours; Voltaren&reg; Gel: 10-14 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9108 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24920=[""].join("\n");
var outline_f24_21_24920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016814\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016849\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017363\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017006\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13713274\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017029\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017238\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9550525\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016851\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016847\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017033\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016852\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016915\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016862\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016912\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016919\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016920\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017406\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771881\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771880\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017265\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370204\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961971\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016951\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/63/15348?source=related_link\">",
"      Diclofenac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/43/8890?source=related_link\">",
"      Diclofenac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/32/20998?source=related_link\">",
"      Diclofenac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=related_link\">",
"      Diclofenac (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_21_24921="Ethinyl estradiol and norelgestromin: Drug information";
var content_f24_21_24921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norelgestromin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/2/27686?source=see_link\">",
"    see \"Ethinyl estradiol and norelgestromin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ortho Evra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Evra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Apply one patch each week for 3 weeks (21 total days); followed by one week that is patch-free. Each patch should be applied on the same day each week (&ldquo;patch change day&rdquo;) and only one patch should be worn at a time. No more than 7 days should pass during the patch-free interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, apply one patch that very same day.",
"     <b>",
"      With a Sunday start, an additional method of contraception (nonhormonal) must be used until after the first 7 days of consecutive administration.",
"     </b>",
"     Each patch change will then occur on Sunday.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Dose starts on first day of menstrual cycle, applying one patch during the first 24 hours of menstrual cycle. No back-up method of contraception is needed as long as the patch is applied on the first day of cycle. Each patch change will then occur on that same day of the week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Additional dosing considerations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     No bleeding during patch-free week/missed menstrual period: If patch has been applied as directed, continue treatment on usual &ldquo;patch change day&rdquo;. If used correctly, no bleeding during patch-free week does not necessarily indicate pregnancy. However, if no withdrawal bleeding occurs for 2 consecutive cycles, pregnancy should be ruled out. If patch has not been applied as directed, and one menstrual period is missed, pregnancy should be ruled out prior to continuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If a patch becomes partially or completely detached for &lt;24 hours: Try to reapply to same place, or replace with a new patch immediately. Do not reapply if patch is no longer sticky, if it is sticking to itself or another surface, or if it has material sticking to it.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If a patch becomes partially or completely detached for &gt;24 hours (or time period is unknown): Apply a new patch and use this day of the week as the new &ldquo;patch change day&rdquo; from this point on.",
"     <b>",
"      An additional method of contraception (nonhormonal) must be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Switching from oral contraceptives or vaginal ring: Complete current cycle and apply the first patch on the day the next pill cycle would be started or ring would be inserted. If there is no menstrual bleeding within 7 days of taking the last active tablet, the patient can initiate the first patch application; however, pregnancy must be ruled out. If patch is applied later than 7 days after the last active pill or removal of the vaginal ring,",
"     <b>",
"      an additional method of contraception (nonhormonal) should be used until after the first 7 days of consecutive administration",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use after childbirth: Therapy should not be started &lt;4 weeks after childbirth. Pregnancy should be ruled out prior to treatment if menstrual periods have not restarted.",
"     <b>",
"      An additional method of contraception (nonhormonal) should be used until after the first 7 days of consecutive administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use after abortion or miscarriage: Therapy may be started immediately if abortion/miscarriage occurs within the first trimester. If therapy is not started within 5 days, follow instructions for first time use. An additional method of contraception (nonhormonal) should be used until after the first 7 days of consecutive administration. If abortion/miscarriage occurs during the second trimester, therapy should not be started for at least 4 weeks. Follow directions for use after childbirth.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Topical: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F168404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ortho Evra&reg;: Ethinyl estradiol 0.75 mg and norelgestromin 6 mg [releases ethinyl estradiol 20 mcg and norelgestromin 150 mcg per day] (1s, 3s)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Evra&reg;: Ethinyl estradiol 0.6 mg and norelgestromin 6 mg [releases ethinyl estradiol 35 mcg and norelgestromin 200 mcg per day] (1s, 3s)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     New patches should be applied on the same day each week. Apply to clean, dry, intact, healthy skin on the buttock, abdomen, upper arm, or back. Avoid areas that will be rubbed by tight clothing. Do not apply to the breasts or to skin that is red, irritated, or cut. Do not apply make-up, creams, lotions, powders, or other topical products to the skin where the patch will be placed. Remove the patch and the plastic liner from the foil pouch, being careful not to remove the clear liner when removing the patch. Apply patch by first peeling back half of the clear protective liner. Avoid touching surface of patch. Apply patch to skin and remove the rest of the liner. Press patch down firmly onto skin using palm of the hand; apply pressure for 10 seconds. Run fingers over entire surface area to smooth out any wrinkles in the patch. The patch should be checked daily to ensure all edges are sticking. When changing the patch each week, the new patch may be applied in the same anatomic area but should be applied to a new spot in that area. Do not use supplemental adhesives or wraps to hold patch into place.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Forgetting to apply the patch at the start of cycle (week 1/day 1): Apply first patch as soon as remembering, using this day of the week as the new &ldquo;patch change day&rdquo; from this point on. An additional method of contraception (nonhormonal) must be used until after the first 7 days of consecutive administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Forgetting to change patch in the middle of the cycle (week 2/day 8 or week 3/day 15): If &lt;48 hours from normal &ldquo;patch change day,&rdquo; apply new patch immediately. No back-up contraception is needed. If &gt;48 hours from normal &ldquo;patch change day,&rdquo; apply a new patch and use this day of the week as the new &ldquo;patch change day&rdquo; from this point on. An additional method of contraception (nonhormonal) must be used until after the first 7 days of consecutive administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Forgetting to remove patch at end of cycle (week 4/day 22): Take off as soon as remembering, start new cycle on usual &ldquo;patch change day.&rdquo;",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Changing the &ldquo;patch change day&rdquo;: The &ldquo;patch change day&rdquo; can be changed to an earlier day in the week by first completing the current cycle. Then, during the &ldquo;patch-free interval&rdquo;, select an earlier day to start the new cycle. Do not allow &gt;7 consecutive patch-free days.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Skin irritation: If patch is in an uncomfortable location, it can be removed and a new patch applied to a different location until the next &ldquo;patch change day.&rdquo;",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     To dispose of patch, fold the sticky sides together and dispose in the trash within a child-resistant container. Do not flush down the toilet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following reactions have been reported with the contraceptive patch. Adverse reactions associated with oral combination hormonal contraceptive agents are also likely to appear with the topical contraceptive patch (frequency difficult to anticipate). See individual oral contraceptive monographs for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast symptoms (22%; including discomfort, engorgement, pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Application site disorder (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety/mood disorders (6%), dizziness (3%), fatigue (3%), migraine (3%), insomnia (&lt;2.5%), malaise (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (3%), pruritus (3%), chloasma (&lt;2.5%), contact dermatitis (&lt;2.5%), erythema (&lt;2.5%), skin irritation (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (8%), menstrual disorders (6%), weight gain (3%), fluid retention (&lt;2.5%), galactorrhea (&lt;2.5%), libido changes (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8%), vomiting (5%), diarrhea (4%), vaginal yeast infection (4%), abdominal distension (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal bleeding (6%), genital discharge (&lt;2.5%), uterine spasm (&lt;2.5%), vaginal discharge (&lt;2.5%), vulvovaginal dryness (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholecystitis (&lt;2.5%), lipid disorders (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Premenstrual syndrome (&lt;2.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abnormal taste, allergic reaction, alopecia, appetite increased, application site reaction, arterial thrombosis, breast cancer, breast fibroadenoma, breast mass, cerebrovascular accident, cervical cancer, cervical dysplasia, cholelithiasis, cholestasis, cholestatic jaundice, cholesterol abnormal, colitis, contact lens intolerance or complication, DVT, eczema, edema, emotional disorder, erythema multiforme, erythema nodosum, glucose abnormal, hepatic adenoma, hepatic lesion, hepatic neoplasm, hyperglycemia, hypertension, hypertensive crisis, insulin resistance, intracranial hemorrhage, MI, migraine with aura, photosensitivity, rash, skin reaction, thrombosis, urticaria, uterine leiomyoma",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethinyl estradiol, norelgestromin, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding, cholestatic jaundice of pregnancy, jaundice with prior combination hormonal contraceptive use",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), headaches with focal neurological symptoms, persistent blood pressure values of &ge;160/100 mm Hg, valvular heart disease with complications, major surgery with prolonged immobilization",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Progestins may be associated with decreased HDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: All combination hormonal contraceptives may increase the risk of venous thromboembolism.",
"     <b>",
"      [U.S. Boxed Warning]: The risk of venous thromboembolism (VTE) may be further increased with use of the contraceptive patch due to increased estrogen exposure in comparison to oral contraceptives.",
"     </b>",
"     Systemic exposure (AUC) of ethinyl estradiol is higher with the patch than from an oral tablet. The increased estrogen exposure may increase the risk of adverse events, including venous thromboembolism. Discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: The topical patch may be less effective in patients weighing &ge;90 kg (198 lb) and an increased incidence of pregnancy has been reported in this population; consider another form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Should not be used in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: The combination hormonal contraceptive patch may have adverse effects similar to those associated with oral contraceptive products. Risk of complications increases with other risk factors such as hypertension, hyperlipidemias, obesity and diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. The topical patch may be less effective in patients weighing &ge;90 kg (198 lb) and an increased incidence of pregnancy has been reported in this population; consider another form of contraception.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011). The manufacturer states that combination hormonal contraceptives should not be started until &ge;4 weeks after delivery in women who choose not to breastfeed, or &ge;4 weeks after a second trimester abortion or miscarriage.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; a nonhormonal form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Ortho Evra Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-20 mcg/24 hrs (1): $40.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; changes in contact lens tolerance. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Evra (AR, BB, BE, BM, BR, BS, BZ, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IT, JM, KP, MT, MY, NI, NL, NO, PA, PE, PL, PR, PT, PY, RU, SE, SG, SK, SR, SV, TH, TT, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Equivalent when applied to abdomen, buttock, upper outer arm, and upper torso",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol and norelgestromin: Rapid; reaches plateau by ~48 hours. Absorption of ethinyl estradiol may be increased with heat exposure due to sauna, whirlpool, or treadmill.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The AUC plasma concentration of ethinyl estradiol at steady state are ~60% higher following use of the patch than with those observed following an oral 35 mcg tablet. Peak plasma concentrations of ethinyl estradiol are 25% lower with the patch than with the tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: Albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norelgestromin and norgestrel: &gt;97%; norelgestromin to albumin and norgestrel to sex-hormone-binding globulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Topical: First-pass effect avoided",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: Forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norelgestromin: Hepatic to norgestrel and others",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Ethinyl estradiol: ~60% greater using the topical patch when compared to oral tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ethinyl estradiol: ~17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norelgestromin: ~28 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Metabolites of ethinyl estradiol and norelgestromin: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/21/24921/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/21/24921/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hendeles S, Galand N, Schwers J, &ldquo;Metabolism of Orally-Administered D-norgestrel in Women,&rdquo;",
"      <i>",
"       Acta Endocrinol (Copenh)",
"      </i>",
"      , 1972, 71(3):557-68.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/21/24921/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/21/24921/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/21/24921/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8687 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24921=[""].join("\n");
var outline_f24_21_24921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708764\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168398\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168414\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168402\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168410\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168403\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168404\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168376\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950038\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168378\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168377\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168412\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168381\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168366\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168411\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168370\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168394\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168372\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168405\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168386\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168384\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168374\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168387\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168365\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168380\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8687|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/2/27686?source=related_link\">",
"      Ethinyl estradiol and norelgestromin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_21_24922="Assessment of the newborn infant";
var content_f24_21_24922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of the newborn infant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Tiffany M McKee-Garrett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/21/24922/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/21/24922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newborn should have a thorough evaluation performed within 24 hours of birth to identify any abnormality that would alter the normal newborn course or identify a medical condition that should be addressed (eg, anomalies, birth injuries, jaundice, or cardiopulmonary disorders) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/1\">",
"     1",
"    </a>",
"    ]. This assessment includes review of the maternal, family, and prenatal history and a complete examination. Depending upon the length of stay, another examination should be performed within 24 hours before discharge from the hospital.",
"   </p>",
"   <p>",
"    The assessment of the newborn infant will be reviewed here. The routine care of the newborn infant is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link\">",
"     \"Overview of the routine management of the healthy newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn history includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of this pregnancy, labor, and delivery including screening tests and risk factors for sepsis.",
"     </li>",
"     <li>",
"      Review of past pregnancies including a history of congenital anomalies, still births,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetic or syndromic conditions.",
"     </li>",
"     <li>",
"      Review of the mother's and father's medical and genetic history. In particular, maternal illnesses prior to and during pregnancy, such as systemic lupus erythematosus, or pregnancy complications, such as gestational diabetes or preeclampsia, may affect fetal growth or lead to other complications. A review of maternal medications should be performed as some maternal medications may have intrauterine effects or be excreted in breast milk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"       \"Principles of medication use during lactation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries and some developing countries, prenatal screening tests are routinely performed. The results of these screening tests should be reviewed as an abnormal finding may be indicative of a medical condition that warrants further evaluation. The following section is a summary of available prenatal testing. A more complete discussion of prenatal screening and care are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial prenatal assessment and patient education\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the first prenatal visit, a standard panel of laboratory tests is usually obtained and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ABO blood type",
"     </li>",
"     <li>",
"      Rhesus (Rh) type and antibody screen to detect antibodies potentially causing hemolytic disease of the newborn",
"     </li>",
"     <li>",
"      Rubella status (immune or nonimmune)",
"     </li>",
"     <li>",
"      Syphilis screen",
"     </li>",
"     <li>",
"      Hepatitis B surface antigen",
"     </li>",
"     <li>",
"      Hematocrit or hemoglobin to detect anemia",
"     </li>",
"     <li>",
"      Urinalysis and urine culture to detect asymptomatic bacteriuria",
"     </li>",
"     <li>",
"      Chlamydia",
"     </li>",
"     <li>",
"      Thyroid function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2008, the American College of Obstetricians and Gynecologists also has recommended universal screening for the human immunodeficiency virus (HIV) in all pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H1276464#H1276464\">",
"     \"Initial prenatal assessment and patient education\", section on 'Human immunodeficiency virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening tests obtained later in pregnancy also impact neonatal assessment. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal diabetes testing (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"       \"Infant of a diabetic mother\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maternal group B streptococcal colonization testing",
"     </li>",
"     <li>",
"      Screening for inherited diseases or birth defects such as Downs syndrome or neural tube defects (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"       \"Prenatal screening and diagnosis of neural tube defects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"       \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fetal ultrasound examination, including fetal survey, estimated fetal weight, and amniotic fluid volume.",
"     </li>",
"     <li>",
"      In mothers with substance abuse, maternal toxicology screening.",
"     </li>",
"     <li>",
"      Screening for tuberculosis in at-risk women (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"       \"Tuberculosis in pregnancy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician performing the initial newborn examination should be familiar with the events surrounding delivery. The duration of labor, duration of rupture of membranes, mode of delivery, the newborn's condition at delivery, and resuscitation, if any, should be reviewed. Infants who required resuscitation are at risk of developing postresuscitative complications, such as hypothermia, hypoglycemia, and central nervous system complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H31#H31\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Postresuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors for sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment should be made for the presence of the following neonatal risk factors for sepsis, particularly for Group B streptococcal (GBS) infection.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrapartum temperature &ge;38&ordm;C (100.4&ordm;F)",
"     </li>",
"     <li>",
"      Membrane rupture &ge;18 hours",
"     </li>",
"     <li>",
"      Delivery at &lt;37 weeks gestation",
"     </li>",
"     <li>",
"      Chorioamnionitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use and duration of maternal intrapartum antibiotic prophylaxis (IAP) also should be noted. An evaluation for sepsis, which includes complete blood count (CBC) and blood cultures should be performed in infants who are ill-appearing, and in asymptomatic infants who have risk factors for sepsis and whose mothers did not receive adequate IAP. &nbsp;Empirical antibiotics should be started in neonates who are ill-appearing or are born to women with suspected or proven chorioamnionitis until laboratory culture results are known. Infants with risk factors who are not treated empirically should be observed in hospital for at least 48 hours. The evaluation and management of infants with risk factors for sepsis, and the management of neonates whose mothers have received IAP are discussed in greater detail separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Maternal and neonatal risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and outcome of sepsis in term and late preterm infants\", section on 'Antibiotic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\", section on 'Management approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination can be performed in the nursery or the mother's room. The area should be warm and quiet, and should have good lighting.",
"   </p>",
"   <p>",
"    The examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation of the infant's general appearance including their body position at rest, body movement, color, and respiratory effort.",
"     </li>",
"     <li>",
"      Body measurements (ie, weight, length, and head circumference) and vital signs.",
"     </li>",
"     <li>",
"      Examination of individual body parts and organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The examination should be conducted in a systematic manner, as a consistent approach ensures that all aspects are evaluated. Although the exact order is not important, the examination is optimized by initially observing the infant's general appearance followed by auscultation of the lungs and heart while the infant is lying quietly. The examination usually proceeds from head to foot as outlined in the following sections. Examination of the hips and spine, which is apt to disturb the infant, usually is performed last. The hips are examined while the infant is supine, then the infant is turned prone to examine the back.",
"   </p>",
"   <p>",
"    The date and time of the examination should be recorded. Findings considered normal close to delivery, eg, a transitional heart murmur, may be abnormal on the second or third day after birth. The examination should include assessment of gestational age. Knowledge of the level of maturity may be important in the interpretation of physical findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=see_link\">",
"     \"Postnatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to touching the infant, much can be learned by observing the appearance of the undressed infant in the resting, non-stimulated state. General inspection should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determination of gender",
"     </li>",
"     <li>",
"      Identification of any deformation (eg, metatarsus adductus) or malformations (eg, cleft lip), which may indicate the presence of a syndrome.",
"     </li>",
"     <li>",
"      Determination of the state of fetal nutrition, by noting the amount of subcutaneous fat on the anterior thighs and gluteal region, or by the amount of Wharton's jelly in the umbilical cord.",
"     </li>",
"     <li>",
"      Assessment of respiratory effort &mdash; Paradoxical breathing movements, in which the abdomen moves outward and the chest wall moves inward in inspiration, are normal. Signs of respiratory distress are abnormal and suggest pulmonary disease. They include rapid breathing, nasal flaring, use of accessory muscles (eg, significant subcostal, intercostal, supraclavicular, or suprasternal retractions), or grunting. The respiratory count should be conducted over a full minute to account for the variable breathing rate in the neonate.",
"     </li>",
"     <li>",
"      Assessment of position and movement &mdash; The newborn's posture at rest usually reflects the intrauterine position. Term newborns who have predominantly been positioned in a vertex presentation typically lie with the hips, knees and ankles flexed. Infants who were in a breech position often have extended legs. A frank breech presentation may result in markedly abducted and externally rotated legs, which may lead to lower extremities deformations. A normal infant moves all extremities symmetrically. Deviation of posture or abnormal movement may be an indication of birth injury or deformation due to intrauterine positioning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link\">",
"       \"Neonatal birth injuries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7639?source=see_link\">",
"       \"Lower extremity positional deformations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of color &mdash; A normal infant appears pink. Acrocyanosis, a bluish appearance of the hands, feet, and perioral area, is common in the first few days after delivery. However, central cyanosis, which is seen best on the tongue and mucous membranes of the mouth, suggests hypoxemia. Bruising also may result in a bluish discoloration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pallor may indicate anemia, caused by acute blood loss at or shortly before delivery or a chronic intrauterine process. A ruddy or plethoric infant may have polycythemia. Infants with polycythemia may appear cyanotic even when they have adequate oxygenation because they have a relatively high amount of unsaturated hemoglobin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link\">",
"     \"Neonatal polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperbilirubinemia results in jaundice, a yellow color best assessed in natural light. Jaundice is unusual in the first 24 hours after birth and almost always is pathologic, and is usually caused by hemolysis and requires evaluation. Intrauterine staining of the skin with meconium may result in a greenish discoloration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant's weight, length, and head circumference should be measured and recorded. These measurements are plotted on standard growth curves to determine the percentile according to gestational age and assess intrauterine growth. The weight is classified as appropriate, large, or small for gestational age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20823?source=see_link\">",
"     \"Large for gestational age newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Average birth weights differ for male and female infants. At 40 weeks gestation, the average weight is 3.6 kg (10th to 90th percentile, 2.9 to 4.2 kg) for males and 3.5 kg (10th to 90th percentile, 2.8 to 4.0 kg) for females [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fronto-occipital head circumference (FOC) should be measured at its maximum (",
"    <a class=\"graphic graphic_picture graphicRef70799 \" href=\"UTD.htm?35/54/36707\">",
"     picture 1",
"    </a>",
"    ). At 40 weeks gestation, the average FOC is 35 cm (10th to 90th percentile, 33 to 37 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/2\">",
"     2",
"    </a>",
"    ]. This measurement may change in the first few days after birth as molding and scalp edema resolve. Some clinicians also measure chest circumference, especially if there is concern about lung growth. Chest circumference normally is within two cm of the head circumference.",
"   </p>",
"   <p>",
"    The length is measured from the top of the head to the bottom of the feet, with the legs fully extended. This measurement is difficult to do accurately. In order to accurately measure a newborn, a length board should be used by two examiners (one to hold the baby and one to measure the baby). At 40 weeks gestation, the average length is 51 cm (10th to 90th percentile, 48 to 53 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs should be recorded every 30 to 60 minutes during the transitional period (first 4 to 6 hours of life) and then every 8 to 12 hours subsequently. Normal routine vital signs for the newborn infant include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature measured with the thermometer in the axilla of 36.1 to 37 degrees C (97.0 to 98.6 degrees F) in an open crib [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory rate of 40 to 60 breaths per minute, which should be counted over a full minute",
"     </li>",
"     <li>",
"      Heart rate of 120 to 160 beats per minute. The heart rate may decrease to 85 to 90 per minute in some term infants during sleep. In these infants, an increase of heart rate with stimulation is reassuring.",
"     </li>",
"     <li>",
"      Blood pressure can be measured using a neonatal size blood pressure cuff in infants with suspected cardiovascular or renal abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link&amp;anchor=H2915571#H2915571\">",
"       \"Etiology, clinical features, and diagnosis of neonatal hypertension\", section on 'Noninvasive measurement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin should be inspected for abnormalities that may indicate an underlying disorder, such as areas of abnormal pigmentation, congenital nevi, macular stains, or hemangiomas. The following is a summary of the benign and transient findings common in normal newborns, which are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Milia are white papules due to retention of keratin and sebaceous material in the pilaceous follicles. They are frequently found on the nose and cheeks, and resolve in the first few weeks of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H9#H9\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Milia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transient pustular melanosis is a generalized eruption of superficial pustules overlying hyperpigmented macules that occurs mostly in African-American newborns. The pustules usually are removed with the first bath so that only the macules remain.",
"     </li>",
"     <li>",
"      Erythema toxicum consists of white papules approximately 1 to 2 mm in size on an erythematous base. The lesions, which contain eosinophils, usually develop on the second or third postnatal day and occur less frequently on the face than on the body, and never on the palms or soles (",
"      <a class=\"graphic graphic_picture graphicRef70785 \" href=\"UTD.htm?36/53/37713\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H4#H4\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Erythema toxicum neonatorum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mongolian spots typically appear as congenital blue-grey, greenish-blue or brown pigmented macules with indefinite borders. The diameter of the lesion may be 10 cm or more. The lesions are results of the delayed disappearance of dermal melanocytes. Although they usually are located on the buttocks and over the base of the spine, these skin lesions can appear anywhere on the body (",
"      <a class=\"graphic graphic_picture graphicRef77805 \" href=\"UTD.htm?29/11/29875\">",
"       picture 3",
"      </a>",
"      ). They predominantly affect African-American and Asian infants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"       \"Benign skin and scalp lesions in the newborn and young infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nevus simplex (often called macular stain, stork bite, or angel kiss) is a pink-red capillary malformation that may occur on the upper eyelids, upper lip, middle of the forehead, or the nape of the neck (where they are known as stork bites). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link&amp;anchor=H4#H4\">",
"       \"Vascular lesions in the newborn\", section on 'Nevus simplex (macular stain)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nevus flammeus, or port-wine stain, is a low flow capillary malformation that can occur anywhere on the body (",
"      <a class=\"graphic graphic_picture graphicRef59124 \" href=\"UTD.htm?18/32/18946\">",
"       picture 4",
"      </a>",
"      ). It may or may not be a benign finding in the newborn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link&amp;anchor=H5#H5\">",
"       \"Vascular lesions in the newborn\", section on 'Port wine stains'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin conditions in the newborn caused by infection and infiltrative disease, congenital skin abnormalities, vascular lesions, and congenital nevi are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"       \"Vesiculobullous and pustular lesions in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=see_link\">",
"       \"Skin nodules in newborns and infants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link\">",
"       \"Vascular lesions in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Head",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection of the head includes noting the size and shape of the head and the presence of abnormal hair, scalp defects, unusual lesions or protuberances, lacerations, and abrasions or contusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fontanelles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fontanelles should be palpated, preferably with the infant in the sitting position. Both fontanelles normally are soft and flat.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior fontanelle is located at the juncture of the metopic, sagittal, and coronal sutures. Its size is variable.",
"     </li>",
"     <li>",
"      The posterior fontanelle is located at the juncture of the sagittal and lambdoid sutures. It usually is open but smaller than 1 cm in diameter.",
"     </li>",
"     <li>",
"      Tense and bulging fontanel in a sitting infant who is not crying may be an indication of raised intracranial pressure, which may be present in patients with a subdural hematoma or bacterial meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H15#H15\">",
"       \"Neonatal birth injuries\", section on 'Subdural hemorrhage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal sutures of the skull (sagittal, coronal, lambdoid, and metopic) should be palpated. Passage through the birth canal may result in molding, a temporary asymmetry of the skull caused by overlapping or overriding of the sutures, particularly the coronal. An asymmetric skull that persists for longer than two to three days after birth or a persistent palpable ridge along the suture line may suggest craniosynostosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=see_link\">",
"     \"Overview of craniosynostosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the sutures normally can be separated soon after delivery, widely split sutures with a full fontanelle may indicate increased intracranial pressure caused by hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link&amp;anchor=H14#H14\">",
"     \"Hydrocephalus\", section on 'Congenital'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and evaluation of macrocephaly in infants and children\", section on 'Hydrocephalus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Craniotabes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniotabes is a soft area of skull bone, usually in the parietal region, that gives a sensation of a ping-pong ball when depressed. It commonly is found in premature infants, and can occur in a term infant whose head rested on the maternal pelvic brim during the last few weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/3\">",
"     3",
"    </a>",
"    ]. Craniotabes can be a pathologic finding in syphilis and rickets, although it usually occurs in normal infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Extracranial findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery can result in the following extracranial birth findings, which are discussed in greater detail separately (",
"    <a class=\"graphic graphic_figure graphicRef53176 \" href=\"UTD.htm?15/3/15411\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal birth injuries\", section on 'Extracranial injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Caput succedaneum is an area of edema over the presenting part of the head. This common condition typically is present at birth, crosses suture lines, and resolves within a few days.",
"     </li>",
"     <li>",
"      Cephalohematomas are subperiosteal collections of blood that are present in 1 to 2 percent of newborns. On palpation, they form a fluctuant mass that does not cross suture lines, which may increase in size after birth, and usually take weeks to months to resolve.",
"     </li>",
"     <li>",
"      Subgaleal hemorrhages are collections of blood between the aponeurosis covering the scalp and the periosteum. Subgaleal hemorrhages extend across suture lines but feel firm and fluctuant. Blood loss from these hemorrhages can be extensive and life threatening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Face",
"    </span>",
"    &nbsp;&mdash;&nbsp;The face is examined for symmetry. Facial palsies and asymmetric crying facies are most obvious when the baby is crying and may go unnoticed in the quiet or sleeping baby.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Facial palsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial palsies are usually seen in infants who are delivered with the use of forceps, and can also be seen in those with a prolonged delivery in mothers with a prominent sacral promontory. Typically, only the mandibular branch of the facial nerve is affected and the infant will have diminished movement on the affected side of the face. The facial palsy is characterized by the loss of the nasolabial fold, partial closing of the eye, and the inability to contract the lower facial muscles on the affected side leading to the appearance of a \"drooping\" mouth. When crying, the mouth is drawn over to the unaffected side.",
"   </p>",
"   <p>",
"    Facial palsies resolve completely in a few days to a few weeks. No treatment is required, with the exception of the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38131?source=see_link\">",
"     artificial tears",
"    </a>",
"    in the affected eye. In addition, it is imperative to ensure that the infant can adequately feed prior to discharge. A persistent palsy may imply a central lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Asymmetric crying facies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymmetric crying facies (ACF) are the result of congenital absence or hypoplasia of the depressor anguli oris muscle, also referred to as Cayler cardiofacial syndrome.",
"   </p>",
"   <p>",
"    Similar to facial palsies, the muscles controlling movement of one side of the mouth are affected, thus there is asymmetry of the face upon crying. Unlike facial palsies, the muscles controlling movement of the upper face are normal; thus, the nasolabial folds are normal, and when the infant cries, the forehead wrinkles and both eyes close normally. This is typically a benign condition and becomes less noticeable as the child gets older.",
"   </p>",
"   <p>",
"    However, ACF has been associated with other anomalies, particularly those of the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/4\">",
"     4",
"    </a>",
"    ]. One prospective study of 5532 infants revealed an incidence of ACF of 0.31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/5\">",
"     5",
"    </a>",
"    ], with two of the seven affected infants having other significant malformations. In another review of 35 infants with ACF, 16 had other associated anomalies, although many of them were minor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/6\">",
"     6",
"    </a>",
"    ]. When ACF is diagnosed, it is prudent to perform a thorough examination for other congenital anomalies, in particular, identifying any cardiovascular abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial examination of the eyes may be difficult to perform because the eyelids often are edematous after delivery. Most infants will open their eyes spontaneously when held vertically in an environment with low ambient light.",
"   </p>",
"   <p>",
"    The examiner should note the position and spacing of the eyes, symmetry of the eyes, width of palpebral fissures, eye color, appearance of the sclera and conjunctiva, condition of the eyelids, pupillary size, and eye movement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spacing &mdash; Hypertelorism, an abnormally wide interpupillary distance, is associated with a large number of syndromes including Apert syndrome (acrocephalosyndactyly type I) and trisomy 13. If eye spacing appears abnormal, the distance between the eyes should be measured and compared to standard values [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symmetry &mdash; Asymmetry of the eyes may be the result of prominent epicanthal folds (skin folds over the medial aspect of the eyes), a difference in the size of the globes, or ptosis. Epicanthal folds rarely are normal and usually suggest a syndrome (eg, Trisomy 21) (",
"      <a class=\"graphic graphic_picture graphicRef64030 \" href=\"UTD.htm?11/15/11505\">",
"       picture 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Palpebral fissures &mdash; Widened or narrow palpebral fissures are normal for some patients but can be part of a syndrome complex in others. Upward slanting from the inner canthus is typically seen in infants with Down syndrome (",
"      <a class=\"graphic graphic_picture graphicRef64030 \" href=\"UTD.htm?11/15/11505\">",
"       picture 5",
"      </a>",
"      ), whereas down slanting palpebral fissures are characteristic of Treacher Collins and Apert syndromes, and narrow short palpebral fissures in DiGeorge syndrome.",
"     </li>",
"     <li>",
"      Eye movement &mdash; The examiner should assess extraocular muscle movement. Symmetrical movement of the eyes should occur as the patient is held vertically and moved gently from side to side. Although asymmetric eye movement is common in the first month of life, asymmetric movement may be an indication of an abnormality within the brain or to cranial nerves III, IV, or VI.",
"     </li>",
"     <li>",
"      Sclerae &mdash; The sclerae normally are white and clear. In premature infants, the sclerae may appear light blue because the darker color of the underlying uveal tissue is transmitted through the thin underdeveloped sclerae [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/8\">",
"       8",
"      </a>",
"      ]. If the sclerae appear deep blue, osteogenesis imperfecta should be considered. In this condition, the discoloration is caused by inadequate development of scleral collagen.",
"     </li>",
"     <li>",
"      Conjunctiva &mdash; The conjunctiva should be examined for hemorrhage, inflammation, or purulent discharge. Subconjunctival hemorrhages can occur spontaneously during birth, but are more common following a traumatic delivery. &nbsp;",
"     </li>",
"     <li>",
"      Cornea &mdash; The corneal diameter in most newborns is approximately 10 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/8\">",
"       8",
"      </a>",
"      ]. Corneal enlargement (&gt;12 mm) suggests glaucoma, especially if accompanied by photophobia, excessive tearing, or corneal haze (",
"      <a class=\"graphic graphic_picture graphicRef50389 \" href=\"UTD.htm?27/25/28049\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=see_link\">",
"       \"Primary infantile glaucoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pupils &mdash; Pupils should be assessed for their shape and reaction to light. Normal pupils are round and constrict in response to a bright light. Pupillary reaction occurs consistently after 32 weeks gestational age but may be apparent in some infants as early as 28 weeks gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/9\">",
"       9",
"      </a>",
"      ]. Defects in the iris (eg, coloboma) should be noted and may be suggestive of a syndrome, such as renal coloboma syndrome or CHARGE syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=see_link&amp;anchor=H10#H10\">",
"       \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Optic disc coloboma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Red reflex &mdash; An ophthalmoscopic examination should determine whether or not a red reflex is present in all neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/10\">",
"       10",
"      </a>",
"      ]. The red reflex test is performed observing both eyes of the infant through an ophthalmoscope with the ophthalmoscope lens power set at \"0\" at a distance approximately 18 inches away from the infant. A normal red reflex emanates from both eyes and is symmetric in character without evidence or opacities or white spots (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"UTD.htm?31/47/32506\">",
"       figure 2",
"      </a>",
"      ). The normal red reflex is seen if the lens and underlying structures are clear. Dark spots in the red reflex, a markedly diminished reflex, presence of a white reflex, or asymmetry of the reflex are indications for referral to an ophthalmologist. Abnormalities of the lens (eg, cataract), vitreous (eg, persistent fetal vasculature), or retina (eg, retinoblastoma) produce a white pupil (leukocoria). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H2#H2\">",
"       \"Approach to the child with leukocoria\", section on 'Causes of leukocoria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ears",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ears are inspected for their position, size, and appearance. The ears are in a normal position if the helix is intersected by a horizontal line drawn from the outer canthus of the eye perpendicular to the vertical axis of the head [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/11\">",
"     11",
"    </a>",
"    ]. If the helix falls below this line, the ears are considered low-set. An ear is posteriorly rotated if its vertical axis deviates more than 10 degrees from the vertical axis of the head.",
"   </p>",
"   <p>",
"    The ears should be inspected for branchial cleft cysts (which may be located in the preauricular area and along the line anterior to the sternocleidomastoid in the neck), sinuses, preauricular skin tags or pits, or dysplastic features. External ear abnormalities increase the risk of additional anomalies of the middle and inner ear, which are associated with hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, external ear malformations often are associated with syndromes of multiple congenital anomalies that include renal malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/13\">",
"     13",
"    </a>",
"    ]. However, patients with isolated minor external ear anomalies (eg, preauricular skin tags or pits) do not appear to have a significant increased risk of renal anomalies. As a result, although controversial, routine renal imaging for patients with isolated minor ear abnormalities appears to be unnecessary unless accompanied by other major malformations or multiple congenital anomaly syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=see_link&amp;anchor=H9#H9\">",
"     \"Congenital anomalies of the ear\", section on 'Preauricular pits'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ear canals should be observed for patency. Visualization of the tympanic membranes is limited by the small size of the ear canal and the presence of vernix and other debris. This examination usually is not done in the newborn period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nose should be examined for its shape and patency. The shape of the nose may be abnormal because of intrauterine deformation or the birth process. In this case, it will return to a normal shape within a few days of birth. An extremely thin or unusually broad nose, or a depressed nasal bridge may occur with some malformation syndromes.",
"   </p>",
"   <p>",
"    The nares may appear asymmetric if the nasal cartilage is dislocated from the vomerine groove (septal deviation). This condition can be distinguished from a positional deformity by depression of the tip of the nose. A dislocated septum appears angled within the nares and does not resume a normal position when released. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H12#H12\">",
"     \"Neonatal birth injuries\", section on 'Nasal septal dislocation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patency of the nares should be established because infants are predominantly nose breathers. This can be accomplished by noting the movement of a piece of cotton or thread placed in front of each naris. Obstruction may be caused by edema related to vigorous suctioning after birth, or be due to anatomical causes, such as choanal atresia. The latter can be tested by passage of a feeding tube or suction catheter through the nose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital anomalies of the nose\", section on 'Choanal atresia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size and shape of the mouth should be assessed. The maxillae and mandible should fit well together and open at equal angles bilaterally. Asymmetry of the mouth (asynclitism) usually is caused by intrauterine position and resolves with time. A small jaw (micrognathia) may be seen in Robin sequence. The lip should be examined for evidence of a cleft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link&amp;anchor=H9#H9\">",
"     \"Syndromes with craniofacial abnormalities\", section on 'Robin sequence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of the interior of the mouth includes examination of the gingiva, tongue, palate, and uvula. The following findings are commonly seen in the neonate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small, white, benign inclusion cysts on the palate, known as Epstein's pearls, are seen in most babies. They often are clustered at the midpoint of the junction between the soft and hard palate.",
"     </li>",
"     <li>",
"      Mucus retention cysts may occur on the gums (mucocele) (",
"      <a class=\"graphic graphic_picture graphicRef75671 \" href=\"UTD.htm?12/31/12790\">",
"       picture 7",
"      </a>",
"      ) or on the floor of the mouth (ranula) (",
"      <a class=\"graphic graphic_picture graphicRef50630 \" href=\"UTD.htm?31/8/31875\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link&amp;anchor=H20#H20\">",
"       \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Mucoceles'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link&amp;anchor=H21#H21\">",
"       \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Ranulas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The frenulum linguae, a band of tissue that connects the floor of the mouth to the tongue, may be unusually short or extend to the tip of the tongue, resulting in ankyloglossia (tongue-tie). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=see_link\">",
"       \"Ankyloglossia (tongue-tie) in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Natal teeth (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60962 \" href=\"UTD.htm?26/52/27456\">",
"       image 1",
"      </a>",
"      ) usually are primary mandibular incisors. Although they most commonly occur as an isolated finding, natal teeth may be associated with a variety of syndromes, such as chondroectodermal dysplasia (Ellis-van Creveld syndrome), pachyonychia congenita, Sotos syndrome, and Hallerman-Streiff syndrome. Treatment may involve observation, smoothing of the incisal edge (to prevent potential discomfort during breastfeeding and ulceration in the floor of the mouth), or extraction. Extraction should be considered if the teeth are not well secured and may be a potential aspiration risk; or if they pose problems with feeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=see_link&amp;anchor=H3#H3\">",
"       \"Developmental defects of the teeth\", section on 'Natal and neonatal teeth'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clefts of the soft or hard palate may be visible by inspection. Palpation may be needed to detect a submucosal cleft [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/15\">",
"       15",
"      </a>",
"      ]. A bifid uvula may be associated with a submucosal cleft.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neck should be assessed for abnormalities, such as masses, decreased mobility, or excessive skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck masses in the newborn infant may be differentiated by their location and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic hygroma, a lymphangioma that is the most common lymphatic malformation in children, typically presents as a painless, transilluminated, soft mass that is located superior to the clavicle.",
"     </li>",
"     <li>",
"      Branchial cleft cysts may be palpated along the anterior margin of the sternocleidomastoid.",
"     </li>",
"     <li>",
"      Hematomas may be the cause of masses in the lower portion of the neck.",
"     </li>",
"     <li>",
"      Thyroglossal duct cyst or enlarged thyroid may be the cause of a midline mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=see_link\">",
"       \"Thyroglossal duct cysts and ectopic thyroid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isolated palpable cervical lymph nodes, up to 12 mm in diameter, are common in healthy newborns [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/3\">",
"       3",
"      </a>",
"      ]. However, lymphadenopathy also may result from congenital infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Torticollis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torticollis, or wry neck, usually results from trauma to the sternocleidomastoid (SCM) muscle caused by birth injury or intrauterine malposition. The injury causes a hematoma or swelling within the muscle. Torticollis also may be caused by developmental abnormalities of the cervical spine. In affected infants, the head is tipped to one side and the chin rotated toward the other. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link\">",
"     \"Acquired torticollis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Excess skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Redundant skin in the neck may be a feature of genetic syndromes. Examples include Turner syndrome, in which the neck appears webbed because of redundant skin along the posterolateral line, and Down syndrome with excess skin at the base of the neck posteriorly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Clavicles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both clavicles should be palpated. Partial or complete absence of the clavicle may occur in congenital syndromes, such as cleidocranial dysostosis. Clavicular fractures typically present with irritability and decreased motion on the affected side because of pain. Signs include tenderness, crepitus, swelling on the bone, and an asymmetric Moro response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H20#H20\">",
"     \"Neonatal birth injuries\", section on 'Clavicle'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Chest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest should be inspected for size, symmetry, and structure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small or malformed thorax may result from pulmonary hypoplasia or neuromuscular disorders.",
"     </li>",
"     <li>",
"      Chest asymmetry may be caused by an absent pectoralis muscle (Poland sequence), or result from a mass or abscess.",
"     </li>",
"     <li>",
"      Pectus excavatum (funnel chest) or pectus carinatum (pigeon breast) may occur as an isolated finding, or as part of congenital syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=see_link\">",
"       \"Pectus carinatum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Chest wall movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ribs and sternum are incompletely ossified in the newborn, resulting in a highly compliant chest wall. Breathing in normal infants may be paradoxical, in which the rib cage moves inward and the abdomen moves outward during inspiration. In respiratory disorders, the high intrathoracic pressures generated to inflate poorly compliant lungs may cause retractions that are intercostal, subcostal, or subxiphoid (substernal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast size and nipple position should be noted. The presence and amount of breast tissue may be helpful in assessment of gestational age. Breast hypertrophy caused by exposure to maternal hormones occurs in both males and females and can be asymmetric. Occasionally, breasts will secrete a thin milky fluid known as \"witch's milk\" for several days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Widely spaced nipples occur in some genetic syndromes (eg, Turner syndrome). If the nipples appear to be widely spaced, measurement of the distance between the nipples should be compared to available normative data [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/16\">",
"     16",
"    </a>",
"    ]. In general, an internipple distance that is &gt;25 percent of chest circumference is considered wide-spaced.",
"   </p>",
"   <p>",
"    Supernumerary nipple, or accessory mammary tissue, is a common finding, occurring with an incidence of approximately 1 in 40 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/17\">",
"     17",
"    </a>",
"    ]. They are more common in African-American infants [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/18\">",
"     18",
"    </a>",
"    ]. Supernumerary nipples are usually found inferior and medial to the true breasts, along the milk line, a vertical line that extends from the axilla to the pubic region. Supernumerary nipples are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3673?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of breast disorders in children and adolescents\", section on 'Accessory breast tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Lungs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant's breathing rate and pattern should be observed. These may fluctuate depending upon the state of wakefulness, and whether the infant is active or crying. The respiratory rate should be counted for a full minute to account for variations in rate and rhythm. A normal rate is 40 to 60 breaths per minute.",
"   </p>",
"   <p>",
"    Infants with respiratory disorders often have tachypnea and retractions. Other signs of respiratory distress include use of accessory respiratory muscles (eg, flaring of the nasal alae) and grunting. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Chest wall movement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auscultation of the lungs should be performed with the infant as quiet as possible. In general, this is best accomplished early in the assessment prior to palpation of the abdomen, head, and neck.",
"   </p>",
"   <p>",
"    Normal breath sounds are bronchovesicular and are heard equally on both sides of the chest. The breath sounds should be clear, although some infants may have scattered rales for a few hours after delivery. Abnormal breath sounds are unusual in the absence of tachypnea or signs of respiratory distress. In infants with respiratory disease, grunting sometimes is audible only with a stethoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Cardiovascular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation through the chest wall determines the apical impulse and locates the position of the heart. Because the right ventricle is dominant in the newborn, the point of maximal impulse is best felt in the area of the left lower sternal border. Palpation also can detect the presence of a heave, tap, or thrill.",
"   </p>",
"   <p>",
"    Auscultation should be performed with a warmed stethoscope while the baby lies quietly. Thorough evaluation necessitates auscultation of all areas of the precordium, as well as the back and axillary areas. The process includes noting the rate and rhythm and listening carefully for the first and second heart sounds, and the presence of a murmur. &nbsp;The heart rate is normally 120 to 160 beats per minute but may decrease to 85 to 90 per minute in some term infants during sleep.",
"   </p>",
"   <p>",
"    Heart sounds usually are heard best along the left sternal border. Prominent heart sounds in the right chest may signify dextrocardia. In general, the first heart sound is a singular sound caused by nearly simultaneous closure of the tricuspid and mitral valves and is best heard at the apex. The second heart sound, best heard at the left upper sternal border, is caused by closure of the pulmonary and aortic valves and normally is split.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Murmurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart murmurs are characterized by the intensity and quality of the sound they create, when they occur in the cardiac cycle, their location, and whether they are transmitted. The intensity of murmurs is graded on a scale of I to VI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the first few days after birth, most newborns have murmurs that are transient and benign. They usually are caused by a patent ductus arteriosus (PDA), or pulmonary branch stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. The latter is more likely if the murmur persists after 24 hours when most PDAs have closed. The PDA murmur is continuous, often described as \"machinery-like\" or harsh in quality. It usually is loudest under the left clavicle (second intercostal space), but may radiate down the left sternal border. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intensity and quality of the murmur and associated findings usually can differentiate innocent murmurs from those associated with heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707667#H2707667\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Murmurs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features associated with innocent murmurs are [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Murmur intensity grade II or less, heard at left sternal border",
"     </li>",
"     <li>",
"      Normal second heart sound",
"     </li>",
"     <li>",
"      No audible clicks",
"     </li>",
"     <li>",
"      Normal pulses",
"     </li>",
"     <li>",
"      No other abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Signs that suggest congenital heart disease are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Murmur intensity grade III or higher",
"     </li>",
"     <li>",
"      Harsh quality",
"     </li>",
"     <li>",
"      Pansystolic duration",
"     </li>",
"     <li>",
"      Loudest at upper left sternal border",
"     </li>",
"     <li>",
"      Abnormal second heart sound",
"     </li>",
"     <li>",
"      Absent or diminished femoral pulses",
"     </li>",
"     <li>",
"      Other abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Pulses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral pulses should be palpated when the infant is quiet. Diminished femoral pulses may indicate coarctation of the aorta, whereas an increased pulse pressure may occur with PDA. If femoral pulses are abnormal, brachial, radial, and pedal pulses should be palpated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdomen should be examined when the infant is quiet. The size and overall appearance should be assessed. The normal abdomen is slightly protuberant. Distension is abnormal and may indicate conditions such as intestinal obstruction, organomegaly, or ascites. The abdomen may be scaphoid in the presence of a diaphragmatic hernia. Many normal infants have diastasis recti, resulting from the nonunion of the two rectus muscles, which may result in an umbilical hernia. Other abdominal wall defects, such as omphalocele or gastroschisis, usually are identified at delivery or prenatally by ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=see_link&amp;anchor=H17#H17\">",
"     \"Care of the umbilicus and management of umbilical disorders\", section on 'umbilical hernia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=see_link\">",
"     \"Obstetrical management of omphalocele\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35464?source=see_link\">",
"     \"Obstetrical management of gastroschisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the abdomen should begin superficially and proceed more deeply, but remain gentle to avoid causing discomfort, which results in the infant crying. Holding the infant's legs in a flexed position and having the infant suck on a pacifier or the examiner's gloved finger may facilitate relaxation of the abdominal wall muscles.",
"   </p>",
"   <p>",
"    The liver edge normally is palpated one to three centimeters below the right costal margin. The liver should be soft with a smooth edge. The spleen usually is not palpable, although some normal infants may have a palpable spleen tip.",
"   </p>",
"   <p>",
"    The kidneys may be palpated through the anterior abdominal wall. One approach to facilitate palpation of the lower poles of the kidneys is to place the fingertips above and below the lower quadrants and apply moderate pressure; this maneuver traps the kidneys between the fingertips. The left kidney is more easily palpable than the right.",
"   </p>",
"   <p>",
"    Any other palpable abdominal mass is abnormal and requires further investigation. Most abdominal masses in newborns are enlarged kidneys caused by hydronephrosis or cystic renal disease. Masses may also result from tumors, such as neuroblastomas or teratomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Umbilical cord",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord is inspected for general appearance, amount of Wharton's jelly, and the umbilical vessels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small cord may indicate poor maternal nutritional status or intrauterine compromise.",
"     </li>",
"     <li>",
"      Erythema surrounding the stump,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an odorous discharge may indicate omphalitis (ie, infection of the umbilicus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=see_link&amp;anchor=H30#H30\">",
"       \"Care of the umbilicus and management of umbilical disorders\", section on 'Omphalitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A single umbilical artery (SUA) is present in approximately 0.2 to 0.6 percent of singleton live births, and at a higher incidence in twin gestations [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/24\">",
"       24",
"      </a>",
"      ]. SUA is associated with an increased rate of chromosomal and other congenital anomalies, including renal abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/25\">",
"       25",
"      </a>",
"      ]. Currently available data demonstrate there is a low risk of a significant renal abnormality in infants with an isolated SUA. As a result, we do not perform further imaging for healthy term infants with a SUA if there is no other identified abnormality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=see_link&amp;anchor=H11#H11\">",
"       \"Care of the umbilicus and management of umbilical disorders\", section on 'Single umbilical artery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genitalia usually are inspected immediately after birth to identify the infant's gender or confirm the prenatal diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Female",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the female infant, the size and location of the labia, clitoris, meatus, and vaginal opening should be assessed. The appearance of the genitalia varies with gestational age. The labia minora and clitoris are prominent in preterm infants, while the labia majora becomes larger as the infant approaches term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=see_link\">",
"     \"Postnatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link&amp;anchor=H3#H3\">",
"     \"Gynecologic examination of the newborn and child\", section on 'History and physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vaginal opening should be fully visible. Many infants have vaginal skin tags, representing the slight protrusion of vaginal epithelium at the posterior fourchette. Withdrawal from maternal hormones often results in a milky white vaginal discharge, which sometimes is blood-tinged.",
"   </p>",
"   <p>",
"    The labia minora should be separated to detect whether the hymen, which normally has some opening, is imperforate (",
"    <a class=\"graphic graphic_figure graphicRef57977 \" href=\"UTD.htm?8/20/8514\">",
"     figure 3",
"    </a>",
"    ). Imperforate hymen can cause hydrometrocolpos, which usually appears as a bulging hymen, especially with crying. Enlargement of the uterus resulting from an imperforate hymen may be detected as a lower midline abdominal mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Male",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of testes, size of the penis, appearance of the scrotum, and the position of the urethral opening should be evaluated.",
"   </p>",
"   <p>",
"    Testes should be palpable in the scrotum or inguinal canal, and be equal in size. Between 2 and 5 percent of full-term and 30 percent of premature male infants are born with an undescended testicle. Testes descend before six months of age in most cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The penis is stretched to assess length. Normal penile length in the term male is 2.5 to 3.5 cm (",
"    <a class=\"graphic graphic_figure graphicRef57977 \" href=\"UTD.htm?8/20/8514\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/26\">",
"     26",
"    </a>",
"    ]. The scrotum of the term male is rugated and pigmented. &nbsp;Enlargement or swelling of the scrotum may be caused by hydroceles, hernias or, rarely, testicular torsion. Hydroceles are fluid collections around the testes, and usually resolve spontaneously. They can be distinguished from hernias by transillumination of the scrotum.",
"   </p>",
"   <p>",
"    Testicular torsion that occurred prenatally presents with an enlarged, firm, nontender testicle with discoloration of the scrotum. In contrast, postnatal torsion presents with acute tenderness and swelling in a testicle that was previously noted to normal on examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/44/712?source=see_link&amp;anchor=H5#H5\">",
"     \"Neonatal testicular torsion\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The foreskin normally is tight or adherent in the newborn; easy retraction usually is not possible for several months to years. Many infants have a small (one mm) white sebaceous (epidermal) cyst at the tip of the foreskin that is benign.",
"   </p>",
"   <p>",
"    The urethral meatus usually can be located without retraction of the foreskin. The position of the urethral meatus should be determined. Abnormalities of the position of the urethral meatus include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypospadias &mdash; Hypospadias is a congenital anomaly of the male urethra that results in abnormal ventral placement of the urethral opening. The location of the displaced urethral meatus may range anywhere within the glans, the shaft of penis, the scrotum, or perineum (",
"      <a class=\"graphic graphic_picture graphicRef58046 \" href=\"UTD.htm?0/44/710\">",
"       picture 9",
"      </a>",
"      ). Circumcision is usually not recommended, because either the preputial skin may be necessary for hypospadias repair or the lack of ventral skin makes circumcision difficult. A pediatric urologist should be consulted in the nursery if there is a question regarding performance of circumcision. Otherwise, infants with hypospadias and bilaterally palpable testes should be referred to urology, usually within three to six months of age unless parental concerns dictate an earlier referral. The evaluation and management of hypospadias is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"       \"Hypospadias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epispadias &mdash; Dorsal location of the meatus (epispadias) is uncommon. It usually is associated with bladder exstrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=see_link\">",
"       \"Clinical manifestations and initial management of infants with bladder exstrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Ambiguous genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings of ambiguous genitalia in a phenotypic female include an enlarged clitoris, fused labial folds, or palpable gonads; and in a phenotypic male, bifid scrotum, severe hypospadias, micropenis, or cryptorchidism. Ambiguous genitalia may signal an intersex disorder. These conditions also may be caused by abnormalities of sexual differentiation or congenital adrenal hyperplasia (CAH).",
"   </p>",
"   <p>",
"    Infants with ambiguous genitalia should be evaluated promptly because of the possibility of adrenal crisis in infants with the salt-wasting form of CAH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .),",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Anus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anus is inspected for its location and patency. An imperforate anus is not always immediately apparent. Imperforate anus may be an isolated finding or part of a syndrome such as VACTERAL association. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to congenital malformations\", section on 'Association'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Trunk and spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spine is directly visualized and palpated along the vertebral column to detect abnormalities, such as a neural tube defect. Soft tissue masses along the spine that are covered with normal skin may be lipomas or myelomeningocele. The gluteal folds should be separated to determine whether or not a sacral cleft or dimple is present. A tuft of hair, hemangioma (",
"    <a class=\"graphic graphic_picture graphicRef72298 \" href=\"UTD.htm?17/3/17471\">",
"     picture 10",
"    </a>",
"    ), or discoloration in the sacrococcygeal area may suggest an underlying vertebral or spinal cord anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\", section on 'Lumbosacral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180221208\">",
"    <span class=\"h3\">",
"     Sacral dimple",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sacral midline dimples in the skin overlying the coccyx, which have a visible intact base, are typically benign with little or no clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. In contrast, sacral dimples that are deep and large (greater than 0.5 cm), fall within the superior portion or above the gluteal crease (&gt;2.5 cm from the anal verge), or are associated with other cutaneous markers for neural tube defects (eg, hypertrichosis, and discoloration), are more likely to be associated with an underlying neural tube defect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. If a sacral dimple has any of these characteristics, an ultrasound should be performed to screen for a neural tube defect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Extremities",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hands and feet &mdash; The hands and feet are inspected for syndactyly (fusion of digits) and polydactyly (extra digits). Syndactyly and polydactyly can be normal variants in a newborn with an otherwise normal exam or may be associated with various syndromes. The presence of a single palmar crease, also known as a simian crease, should be noted. A single unilateral palmar crease occurs in 5 to 10 percent of the normal population [",
"      <a class=\"abstract\" href=\"UTD.htm?24/21/24922/abstract/26\">",
"       26",
"      </a>",
"      ] and is more common in newborns with Trisomy 21. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extremity movement &mdash; The extremities should move spontaneously and equally. Decreased movement of one limb may be because of pain caused by a fracture or paralysis due to a brachial plexus injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=see_link&amp;anchor=H19#H19\">",
"       \"Neonatal birth injuries\", section on 'Fractures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brachial plexus injury typically occurs when the cervical, or rarely the upper thoracic, nerve roots are stretched during delivery. The pattern of injury is dependent upon which cervical roots are involved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H32#H32\">",
"       \"Brachial plexus syndromes\", section on 'Congenital brachial plexus palsy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      C5 and C6 injury (Erb's palsy) accounts for approximately 50 percent of cases. Weakness involves the deltoid and infraspinatus muscles (mainly C5) and biceps (mainly C6). As a result, the upper arm is adducted and internally rotated, and the forearm is extended, while hand and wrist movement are preserved.",
"     </li>",
"     <li>",
"      C5 to C7 injury (Erb's palsy plus) accounts for approximately 35 percent of cases and manifests as adduction and internal rotation of the arm, extension and pronation of the forearm, and flexion of the wrists and fingers (the \"waiter's tip\" posture).",
"     </li>",
"     <li>",
"      C5 to T1 injury presents with arm paralysis and some sparing of finger flexion.",
"     </li>",
"     <li>",
"      C7 to T1 injury is characterized by a flail arm and Horner's syndrome.",
"     </li>",
"     <li>",
"      C8 to T1 injury (Klumpke's palsy) is the most infrequent pattern and manifests as isolated hand paralysis and Horner's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Hips",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hips should be examined to detect developmental dysplasia of the hip (DDH). The examination for hip instability must be performed gently and with the infant quiet and relaxed. Techniques to detect hip instability (eg, Ortolani and Barlow maneuvers) use adduction and posterior pressure to feel for dislocation, and abduction and elevation to feel for reduction. The sensation of dislocation or reduction is distinct and best described as a \"jerk\" or \"clunk\" and differs from that of benign joint popping or tendon snapping. Risk factors for DDH include female gender, in utero breech position, and a positive family history.",
"   </p>",
"   <p>",
"    The epidemiology, diagnosis and management of DDH are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=see_link\">",
"     \"Treatment and outcome of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn neurologic examination includes an assessment of the infant's level of alertness, spontaneous motor activity, tone, muscle strength, and primitive reflex responses and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=see_link\">",
"     \"Neurological examination of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=see_link\">",
"       \"Patient information: Newborn appearance (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of a newborn infant is generally performed within 24 hours of life to identify any abnormality that would alter the normal newborn course or identify a medical condition that should be addressed. It includes review of the maternal, family, and prenatal history and a complete examination.",
"   </p>",
"   <p>",
"    The newborn history includes the review of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parent's medical and genetic history. In particular, any maternal illnesses prior to and during pregnancy, and the use of maternal medications should be noted. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Past pregnancies including a history of congenital anomalies, still births,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetic or syndromic conditions (see",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Prenatal screening tests (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening tests'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Events surrounding delivery (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Delivery'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Risk factors for sepsis (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors for sepsis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination should be conducted in a systematic and consistent manner. &nbsp;(See",
"    <a class=\"local\" href=\"#H6\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It generally begins with observation of the infant's general appearance including",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      body position at rest, body movement, color, and respiratory effort. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Auscultation of the lung and heart typically follows as the infant usually is lying quietly, which optimizes this portion of the examination. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Lungs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Cardiovascular system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment than proceeds with examination of individual body parts and organs from head to toes, body measurements (ie, weight, length, and head circumference) and measurement of vital signs (see appropriate sections for each body organ and part) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Measurements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Vital signs'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Pediatrics, American College of Obstetricians and Gynecologists; Guidelines for Perinatal Care, 6th Ed, American Academy of Pediatrics, Elk Grove Village, IL 2008.",
"    </li>",
"    <li>",
"     Lissauer, T. Physical examination of the newborn. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 1, p.485.",
"    </li>",
"    <li>",
"     Southgate WM, Pittard WB. Classification and physical examination of the newborn infant. In: Care of the High-Risk Neonate, 5th, Klaus MH, Fanaroff AA (Eds), WB Saunders, Philadelphia 2001. p.100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/4\">",
"      Rioja-Mazza D, Lieber E, Kamath V, Kalpatthi R. Asymmetric crying facies: a possible marker for congenital malformations. J Matern Fetal Neonatal Med 2005; 18:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/5\">",
"      Lahat E, Heyman E, Barkay A, Goldberg M. Asymmetric crying facies and associated congenital anomalies: prospective study and review of the literature. J Child Neurol 2000; 15:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/6\">",
"      Caksen H, Odaba D, Tuncer O, et al. A review of 35 cases of asymmetric crying facies. Genet Couns 2004; 15:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/7\">",
"      Feingold M, Bossert WH. Normal values for selected physical parameters: an aid to syndrome delineation. Birth Defects Orig Artic Ser 1974; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     Gupta BK, Hamming NA, Miller MT. The Eye. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 8th, Fanaroff AA, Martin RJ, Walsh MC (Eds), Mosby, St Louis 2006. p.1721.",
"    </li>",
"    <li>",
"     Hernandez P, Hernandez J. Physical Assessment of the Newborn. In: Assessment and Care of the Well Newborn, Thureen PJ, et al (Eds), WB Saunders, Philadelphia 1999. p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/10\">",
"      American Academy of Pediatrics, Section on Ophthalmology, American Association for Pediatric Ophthalmology And Strabismus, et al. Red reflex examination in neonates, infants, and children. Pediatrics 2008; 122:1401.",
"     </a>",
"    </li>",
"    <li>",
"     Hudgins L, Cassidy SB. Congenital Anomalies. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 8th, Fanaroff AA, Martin RJ, Walsh MC (Eds), Mosby, St Louis 2006. p.561.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/12\">",
"      Roth DA, Hildesheimer M, Bardenstein S, et al. Preauricular skin tags and ear pits are associated with permanent hearing impairment in newborns. Pediatrics 2008; 122:e884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/13\">",
"      Wang RY, Earl DL, Ruder RO, Graham JM Jr. Syndromic ear anomalies and renal ultrasounds. Pediatrics 2001; 108:E32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/14\">",
"      Deshpande SA, Watson H. Renal ultrasonography not required in babies with isolated minor ear anomalies. Arch Dis Child Fetal Neonatal Ed 2006; 91:F29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/15\">",
"      Habel A, Elhadi N, Sommerlad B, Powell J. Delayed detection of cleft palate: an audit of newborn examination. Arch Dis Child 2006; 91:238.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Normal standards. In: Smith's Recognizable patterns of Human Malformation, 6th, Elsevier Saunders, Philadelphia 2006. p.851.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/17\">",
"      Mimouni F, Merlob P, Reisner SH. Occurrence of supernumerary nipples in newborns. Am J Dis Child 1983; 137:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/18\">",
"      de Almeida CM, Gomide MR. Prevalence of natal/neonatal teeth in cleft lip and palate infants. Cleft Palate Craniofac J 1996; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/19\">",
"      Arlettaz R, Archer N, Wilkinson AR. Natural history of innocent heart murmurs in newborn babies: controlled echocardiographic study. Arch Dis Child Fetal Neonatal Ed 1998; 78:F166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/20\">",
"      Hansen LK, Birkebaek NH, Oxh&oslash;j H. Initial evaluation of children with heart murmurs by the non-specialized paediatrician. Eur J Pediatr 1995; 154:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/21\">",
"      McCrindle BW, Shaffer KM, Kan JS, et al. Cardinal clinical signs in the differentiation of heart murmurs in children. Arch Pediatr Adolesc Med 1996; 150:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/22\">",
"      Smythe JF, Teixeira OH, Vlad P, et al. Initial evaluation of heart murmurs: are laboratory tests necessary? Pediatrics 1990; 86:497.",
"     </a>",
"    </li>",
"    <li>",
"     Lissauer T. Physical examination of the newborn. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 7th, Fanaroff AA, Martin RJ, Walsh MC (Eds), Mosby, St Louis 2006. p.513.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/24\">",
"      Klatt J, Kuhn A, Baumann M, Raio L. Single umbilical artery in twin pregnancies. Ultrasound Obstet Gynecol 2012; 39:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/25\">",
"      Murphy-Kaulbeck L, Dodds L, Joseph KS, Van den Hof M. Single umbilical artery risk factors and pregnancy outcomes. Obstet Gynecol 2010; 116:843.",
"     </a>",
"    </li>",
"    <li>",
"     Hernandez P, and Hernandez J. Physical Assessment of the Newborn. In: Assessment and Care of the Well Newborn, Thureen PJ, et al (Eds), WB Saunders, Philadelphia 1999. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/27\">",
"      Kriss VM, Desai NS. Occult spinal dysraphism in neonates: assessment of high-risk cutaneous stigmata on sonography. AJR Am J Roentgenol 1998; 171:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/28\">",
"      Robinson AJ, Russell S, Rimmer S. The value of ultrasonic examination of the lumbar spine in infants with specific reference to cutaneous markers of occult spinal dysraphism. Clin Radiol 2005; 60:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/29\">",
"      Gibson PJ, Britton J, Hall DM, Hill CR. Lumbosacral skin markers and identification of occult spinal dysraphism in neonates. Acta Paediatr 1995; 84:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/30\">",
"      Sneineh AK, Gabos PG, Keller MS, Bowen JR. Ultrasonography of the spine in neonates and young infants with a sacral skin dimple. J Pediatr Orthop 2002; 22:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/31\">",
"      Ben-Sira L, Ponger P, Miller E, et al. Low-risk lumbar skin stigmata in infants: the role of ultrasound screening. J Pediatr 2009; 155:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/32\">",
"      Drolet BA. Cutaneous signs of neural tube dysraphism. Pediatr Clin North Am 2000; 47:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/21/24922/abstract/33\">",
"      Zywicke HA, Rozzelle CJ. Sacral dimples. Pediatr Rev 2011; 32:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4984 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.14-B56043E255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24922=[""].join("\n");
var outline_f24_21_24922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors for sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Head",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fontanelles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sutures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Craniotabes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Extracranial findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Face",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Facial palsies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Asymmetric crying facies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ears",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mouth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Masses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Torticollis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Excess skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Clavicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Chest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Chest wall movement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Lungs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Auscultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Cardiovascular system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Murmurs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Pulses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Genitalia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Female",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Male",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Anus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Trunk and spine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H180221208\">",
"      - Sacral dimple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Hips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4984|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/52/27456\" title=\"diagnostic image 1\">",
"      Newborn with natal teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4984|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/3/15411\" title=\"figure 1\">",
"      Neonatal extracranial and intracranial birth injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/47/32506\" title=\"figure 2\">",
"      Red reflex interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/20/8514\" title=\"figure 3\">",
"      Hymen anatomic variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4984|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/54/36707\" title=\"picture 1\">",
"      Head circumference measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/53/37713\" title=\"picture 2\">",
"      Erythema toxicum face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/11/29875\" title=\"picture 3\">",
"      Mongolian spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18946\" title=\"picture 4\">",
"      Port wine stain - V2 infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/15/11505\" title=\"picture 5\">",
"      Down syndrome facies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/25/28049\" title=\"picture 6\">",
"      Glaucoma corneal enlrgmnt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/31/12790\" title=\"picture 7\">",
"      Mucoceles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/8/31875\" title=\"picture 8\">",
"      Ranula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/710\" title=\"picture 9\">",
"      Hypospadias composite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/3/17471\" title=\"picture 10\">",
"      Lumbosacral hemangioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44615?source=related_link\">",
"      Ankyloglossia (tongue-tie) in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=related_link\">",
"      Approach to congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=related_link\">",
"      Approach to the child with leukocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41721?source=related_link\">",
"      Care of the umbilicus and management of umbilical disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24966?source=related_link\">",
"      Clinical manifestations and initial management of infants with bladder exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=related_link\">",
"      Congenital anomalies of the ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3946?source=related_link\">",
"      Etiology and evaluation of macrocephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=related_link\">",
"      Etiology, clinical features, and diagnosis of neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/21/20823?source=related_link\">",
"      Large for gestational age newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7639?source=related_link\">",
"      Lower extremity positional deformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22265?source=related_link\">",
"      Neonatal birth injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/712?source=related_link\">",
"      Neonatal testicular torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=related_link\">",
"      Neurological examination of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35464?source=related_link\">",
"      Obstetrical management of gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=related_link\">",
"      Obstetrical management of omphalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3673?source=related_link\">",
"      Overview of breast disorders in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=related_link\">",
"      Overview of craniosynostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=related_link\">",
"      Patient information: Newborn appearance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22068?source=related_link\">",
"      Postnatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=related_link\">",
"      Primary infantile glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6840?source=related_link\">",
"      Skin nodules in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=related_link\">",
"      Thyroglossal duct cysts and ectopic thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21254?source=related_link\">",
"      Treatment and outcome of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=related_link\">",
"      Treatment and outcome of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_21_24923="Classification of BOS";
var content_f24_21_24923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of bronchiolitis obliterans syndrome after lung transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pulmonary function criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BOS 0",
"       </td>",
"       <td>",
"        FEV1 &gt;90 percent baseline",
"        <strong>",
"         and",
"        </strong>",
"        FEF 25-75 that is &gt;75 percent of baseline value*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BOS 0-p (potential)",
"       </td>",
"       <td>",
"        FEV1 81 to 90 percent baseline",
"        <strong>",
"         and/or",
"        </strong>",
"        FEF 25-75 that is &le;75 percent of baseline value*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BOS 1",
"       </td>",
"       <td>",
"        FEV1 66 to 80 percent of baseline value*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BOS 2",
"       </td>",
"       <td>",
"        FEV1 51 to 65 percent of baseline value*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BOS 3",
"       </td>",
"       <td>",
"        FEV1 &le;50 percent of baseline value*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Baseline defined as the average of the best two FEV1 values after transplant. Decline in FEV1 is determined by two measurements at least one month apart. FEF 25-75 is the forced expiratory flow rate achieved between 25 and 75 percent of the total expiratory time.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Estenne M, Maurer JR, Bohler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24923=[""].join("\n");
var outline_f24_21_24923=null;
var title_f24_21_24924="Inherited causes RTA";
var content_f24_21_24924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inherited primary causes of renal tubular acidosis (RTA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Type 1 (distal) RTA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal recessive with deafness",
"       </td>",
"       <td>",
"        ATP6V1B1",
"       </td>",
"       <td>",
"        2p13",
"       </td>",
"       <td>",
"        B1 subunit of H-ATPase",
"       </td>",
"       <td>",
"        Presents in infancy with severe metabolic acidosis, poor growth, rickets, and nephrocalcinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal recessive without deafness",
"       </td>",
"       <td>",
"        ATP6V0A4",
"       </td>",
"       <td>",
"        7q33-q34",
"       </td>",
"       <td>",
"        a4 subunit of H-ATPase",
"       </td>",
"       <td>",
"        Presents in infancy with severe metabolic acidosis, poor growth, rickets, and nephrocalcinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        SLC4A1",
"       </td>",
"       <td>",
"        17q21-q22",
"       </td>",
"       <td>",
"        Chloride-bicarbonate exchanger",
"       </td>",
"       <td>",
"        Presents later in life (eg, adolescence and adulthood) with mild/moderate metabolic acidosis, hypercalciuria, nephrolithiasis or nephrocalcinosis, osteomalacia, and erythrocytosis; may be associated with hereditary spherocytosis and southeast Asian ovalocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Type 2 (proximal) RTA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        SLC4A4",
"       </td>",
"       <td>",
"        4q21",
"       </td>",
"       <td>",
"        Sodium bicarbonate cotransporter",
"       </td>",
"       <td>",
"        Severe hypokalemic, hyperchloremic, metabolic acidosis, growth retardation, and ocular abnormalities (glaucoma, cataracts, and band keratopathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Short stature and metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Type 3 (mixed) RTA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Carbonic anhydrase II",
"       </td>",
"       <td>",
"        8q22",
"       </td>",
"       <td>",
"        Carbonic anhydrase II",
"       </td>",
"       <td>",
"        Mixed RTA, osteopetrosis, cerebral calcification, and mental retardation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24924=[""].join("\n");
var outline_f24_21_24924=null;
var title_f24_21_24925="US recs cerv cancer screen";
var content_f24_21_24925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cervical cancer screening recommendations from US professional organizations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Population*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age to initiate",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age to discontinue",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Recommended screening test and frequency",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Post hysterectomy for benign disease",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        HPV vaccination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Age 21 to 29",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age &gt;30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        ACS/ASCCP/ASCP (2012)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        21",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        65",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Cytology every three years",
"       </td>",
"       <td>",
"        Co-testing HPV and cytology every five years (preferred)",
"       </td>",
"       <td rowspan=\"2\">",
"        Not indicated",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Follow age-specific recommendation (same as unvaccinated women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytology every three years (acceptable)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        USPSTF (2012)",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        21",
"       </td>",
"       <td rowspan=\"2\">",
"        65",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Cytology every three years",
"       </td>",
"       <td>",
"        Cytology every three years",
"       </td>",
"       <td rowspan=\"2\">",
"        Not indicated",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Follow age-specific recommendation (same as unvaccinated women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternative: co-testing HPV and cytology every five years",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        ACOG (2012)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        21",
"       </td>",
"       <td rowspan=\"2\">",
"        65",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Cytology every three years",
"       </td>",
"       <td>",
"        Co-testing HPV and cytology every five years (preferred)",
"       </td>",
"       <td rowspan=\"2\">",
"        Not indicated**",
"       </td>",
"       <td rowspan=\"2\">",
"        Follow age-specific recommendation (same as unvaccinated women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytology every three years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACS: American Cancer Society; ASCCP: American Society for Colposcopy and Cervical Pathology; ASCP: the American Society for Clinical Pathology; USPSTF: United States Preventive Services Task Force; ACOG: American College of Obstetricians and Gynecologists.",
"     <br/>",
"     * These guidelines are intended for the general population and are not intended for women who have a history of cervical cancer, high-grade cervical precancers, DES in utero exposure, or who are immunocompromised, as with HIV infection.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Regardless of the age of sexual initiation or other risk factors.",
"     <br/>",
"     &Delta; For women with evidence of adequate negative prior screening (three consecutive negative cytology results or two consecutive negative co-tests with the previous 10 years, with the most recent test within the previous 5 years) and no history of CIN 2 or greater within the last 20 years. Screening should not be resumed for any reason, even if a woman has a new sexual partner.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     For women who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2, CIN 3 in the past 20 years, or a history of cervical cancer ever. Evidence of adequate negative prior screening not required.",
"     <br/>",
"     &sect; For women with evidence of adequate negative prior screening, specified as three consecutive negative cytology results or two consecutive negative co-tests within the previous 10 years, with the most recent test within the previous 5 years.",
"     <br/>",
"     &yen; For women who want to lengthen the screening interval.",
"     <br/>",
"     &Dagger; For women who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2, CIN 3, or cervical cancer.",
"     <br/>",
"     &dagger; For women who have had three or more negative cytology test results in a row, or two consecutive negative co-tests in the past 10 years, with the most recent within the past 5 years.",
"     <br/>",
"     ** For women who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2, CIN 3, or cervical cancer. Women in whom a negative history cannot be documented should continue to be screened.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Saslow D, Solomon D, Lawson H, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012.",
"      </li>",
"      <li>",
"       Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880.",
"      </li>",
"      <li>",
"       Cervical cytology screening. ACOG Practice Bulletin No. 131. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120:1222.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24925=[""].join("\n");
var outline_f24_21_24925=null;
var title_f24_21_24926="Muscle length and force";
var content_f24_21_24926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Muscle length and force",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 470px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperinflation (decreased muscle length) causes a reduced maximal inspiratory pressure (MIP) in many patients with COPD. The MIP is 100 percent of its predicted value when the muscle length is in its normal range. MIP decreases as muscle length decreases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24926=[""].join("\n");
var outline_f24_21_24926=null;
var title_f24_21_24927="Galactocele PI";
var content_f24_21_24927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blocked milk duct (galactocele)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blocked or plugged ducts are areas of the breast where the flow of milk is blocked. They can stretch the nearby breast tissue and cause a painful breast lump (as shown by the arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_21_24927=[""].join("\n");
var outline_f24_21_24927=null;
